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ABSTRACT 
Hypercholesterolemia and Microvascular Dysfunction:  
Altered Mechanisms and Interventional Strategies  
 
Phoebe Stapleton 
 
Cardiovascular disease has a number of risk factors and confounding variables associated 
with the development and progression of the condition. Hypercholesterolemia is one of the few 
independent risk factors of peripheral vascular disease (PVD) and coronary artery disease (CAD) 
with causes stemming from a genetic predisposition and lifestyle management. The primary 
symptom of these diseases can be described as an endothelial cell dysfunction, which 
hypercholesterolemia can exacerbate, leading to a pro-inflammatory state of elevated oxidant 
stress and significant reduction in nitric oxide (NO) bioavailability, a key mediator of 
endothelium-dependent dilation. This environment can culminate into an impairment of the 
vascular reactivity due to mechanical and metabolic alterations. 
The mechanical microvascular remodeling is evident within dyslipidemia producing a 
decrease in vascular perfusion; however there are significant differences between the remodeling 
within the condition of hypercholesterolemia leading to an early evolution of MCP-1 and 
increased wall stiffness and thickness and later progression of  hyperlipidemia leading to an 
increase in TNF-α and microvascular rarefaction.   
While the reduction in NO bioavailability, due to a reduced production or oxidative 
scavenge, leads to a maintained yet altered mechanism of peripheral skeletal muscle arteriolar 
endothelium dependent dilation with a shift to the reliance on increased production of 
metabolites of arachidonic acid metabolism, via the cyclooxygenase and lipoxygenase enzymatic 
pathways. These metabolites include 12- and 15-lipoxygenase and prostacyclin, with strong 
dilator effects, in addition to, thromboxane A2 a profound vasoconstrictor. The culmination of 
these products leads to a net reduced dilator effect evident in animals with genetic 
hypercholesterolemia. 
Current interventions include a number of cholesterol lowering prescriptions and the 
inclusion of a regular exercise program, which have been shown to reduce cholesterol and 
improve the cardiovascular symptoms. Considerable attention has been given to the molecular 
mechanisms leading to the improvement of microvascular endothelial dysfunction and 
subsequent vascular reactivity; however the mechanistic consequences of these treatments are 
not well understood within the realms of inflammation, oxidative stress, and vascular reactivity. 
In both the hypercholesterolemic and normocholesterolemic groups the greatest benefit, with 
respect to inflammation and oxidant stress, was seen in the exercise only groups. Unexpectedly, 
the hypercholesterolemic groups saw no improvement in vascular reactivity to any of the 
interventions; while the normocholesterolemic group presented detrimental results to the 
vascular reactivity of the pharmaceutically treated animals. Therefore, the mechanistic and 
mechanical outcomes associated with the reported pleiotropic effects of the cholesterol lowering 
treatments warrants further study specific to hyper- and normocholesterolemic conditions.   
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Introduction 
While hypercholesterolemia, defined as excessively high plasma cholesterol levels, has 
emerged as a strong risk factor for cardiovascular disease (CVD).  Data acquired by the National 
Health and Nutrition Examination Survey (NHANES) 2005–2006 found that the mean total 
serum cholesterol for Americans over the age of 20 was 199 mg/dl, approximating the American 
Heart Association (AHA) recommended level of 200 mg/dl (1). Unfortunately, 16% of adults 
were found to have total cholesterol levels of more than 240 mg/dl, a level considered by the 
AHA to carry twice the CVD risk of those individuals at the desired level (1; 55).  
Total cholesterol can be broken down into a diagnostic lipoprotein profile, including high 
density lipoprotein (HDL), low density lipoprotein (LDL), intermediate density lipoproteins 
(IDL), very low density lipoprotein (VLDL), chylomicron remnants, and triglycerides.  With 
respect to these markers, the AHA publishes recommendations summarized in Table 1 (1).  HDL 
is considered to be beneficial as higher levels have been correlated with reduced risk of negative 
cardiovascular events, in large measure by promoting reverse cholesterol transport, an anti-
atherogenic process resulting in cholesterol from peripheral tissues returning to the liver for 
subsequent processing (1).  Elevated LDL cholesterol and triglycerides are considered 
detrimental as their increased concentration is well correlated with poor cardiovascular outcomes 
(1; 87).  Current research has also suggested that IDL, VLDL, and chylomicron remnants may 
also play an active role in PVD and CAD development (87). 
As high total cholesterol levels are considered to be a major independent risk factor for 
development of PVD and CAD, considerable attention has been directed toward evaluating the 
impact and mechanisms of cholesterol lowering therapies and interventions for cardiovascular 
outcomes (55; 87; 88). Cholesterol has been shown to interrupt and alter vascular structure, 
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mechanics, and function as it builds within the lining of the vascular wall, and can interfere with 
endothelial function leading to lesions, plaques, occlusion, and emboli; along with a reduction in 
healing, recovery, and appropriate management of ischemia/reperfusion injury (15; 35; 38; 45; 
92).  With specific relevance to the microcirculation, it has been clearly demonstrated that 
evolution of hypercholesterolemia is associated with endothelial cell dysfunction (8; 21; 35; 43; 
93; 109). Additionally, reports have shown a near-complete abrogation in vascular nitric oxide 
(NO) bioavailability, elevated oxidant stress, and the creation of a strongly pro-inflammatory 
condition; symptoms which can culminate in profound impairments to vascular reactivity (8; 13; 
27; 46; 77; 93; 95; 96; 103; 107). Investigation into vascular consequences of chronic 
hypercholesterolemia, the mechanisms through which these consequences occur, and the 
potentially beneficial effects of ameliorative therapies have received considerable attention in 
recent years (2; 4; 20; 27; 38; 77; 87; 91; 93). 
Although a substantial risk factor for CVD, hypercholesterolemia has also been 
demonstrated to be one which can be manageable, as summarized in meta-analytic projects 
which have supported the use of pharmaceutical interventions to reduce cholesterol, with the 
outcome of lowering cardiovascular event incidence (4; 6).  However, these studies have 
evaluated few vascular reactivity benefits associated independently of the overall cholesterol 
lowering benefit. Therefore, effective interventional treatment can be problematic, as the 
presence of specific genetic risk factors are frequently present.  The condition of familial 
hypercholesterolemia (FH) is an inherited autosomal dominant disorder caused by variations to 
the low density lipoprotein receptor (LDLR) gene, preventing effective function and dramatically 
elevated levels of circulating LDL (52). While the phenotypic effects of the homozygous 
condition are more severe, the prevalence of the heterozygous condition affects approximately 1 
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in 500 individuals (25). Normally, LDL transports cholesterols and fats through the aqueous 
bloodstream to the cell surface where LDLR mediates its endocytosis, a process that is rendered 
ineffective in FH.   A second inherited cause of hypercholesterolemia is familial combined 
hyperlipidemia (FCH), also known as type III hyperlipidemia, which presents high cholesterol 
and high triglyceride levels stemming from a number of gene polymorphisms (58).  Interestingly, 
while the dyslipidemic profile of these two conditions differs, there is a striking similarity in the 
poor vascular outcomes (92).  
Hypercholesterolemia and Vascular Dysfunction 
The vascular endothelium, a single cell layer on the inner surface of all vessels, is capable 
of producing numerous bioactive molecules, thereby acting as an autocrine, paracrine, and 
endocrine organ (20). In a normal system, endothelial cells maintain vascular tone via 
endothelium-derived relaxing factors including NO, prostacyclin, and endothelium-derived 
hyperpolarizing factors (43) in an integrated balance with sympathetic and myogenic tone as 
well as parenchymal cell influences.  These molecules help to regulate the homeostasis of the 
vascular system by adjusting to a number of systemic demands on blood flow, coagulation, 
inflammation, platelet aggregation, and signal transduction, with any decay in efficacy 
considered as dysfunction (26).  
Nitric oxide (NO), a gas synthesized from the amino acid L-arginine through the enzyme 
nitric oxide synthase (NOS), has been widely considered as an endothelium-dependent regulator 
of vascular tone, with additional roles in preventing platelet activation, inhibiting oxidative 
stress, cell growth, and inflammation, among others (46; 66).  Asymmetric dimethylarginine 
(ADMA) is an endogenous inhibitor of NOS through competitive inhibition with L-arginine 
(13). Given recent studies demonstrating an increased endogenous production of ADMA in 
3
hypercholesterolemia and the inverse relationship between NO production and ADMA 
concentration, ADMA is currently under intensive evaluation as an additional risk factor for 
CVD (13; 103).  
Previous studies within our laboratory and others have shown that dilator reactivity in 
response to NO-dependent stimuli is moderately impaired in hypercholesterolemic mice as 
compared to responses in control animals (36; 60; 90; 93; 96; 97; 110). This reduction is not due 
to an inability to react to the NO signal, as vessels are able to respond normally to NO donors, 
rather there is a reduction in the bioavailability of NO within vasculature either via deficits in 
production or due to increased oxidant scavenging (109).  Additional data suggest that NO-
mediated endothelium-dependent responses within a hypercholesterolemic milieu may differ 
between conduit vessels and the microcirculation, as peripheral resistance arterioles have a 
greater sensitivity to local metabolite production (29; 40; 105). Further, in hypercholesterolemic 
mice and diet induced hypercholesterolemic rabbits, compensatory mechanisms evolve to 
maintain endothelium-dependent dilation as a result of a decrease in NO bioavailability, and 
appear to involve altered patterns of arachidonic acid metabolism involving both the 
cyclooxyegnase and lipoxygenase pathways (2; 3; 21; 78; 93; 106).  Arachidonic acid action 
within hypercholesterolemia is not limited to metabolite production inducing dilation, such as 
prostacyclin, which remains constant, but includes the production of thromboxane A2 (TXA2), a 
potent vasoconstrictor (27; 75). Hypercholesterolemic animals have shown a limitation to 
arachidonic acid induced dilation due to a counteractive increase in TXA2 production during 
metabolism (15). While, similar hypercholesterolemic animals have shown an improvement in 
vascular reactivity and atherosclerotic lesions in animals who are thromboxane receptor deficient 
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(27; 49; 76). This mechanism may also lead to the reductions of endothelium dependent dilation 
seen in hypercholesterolemia.  
The mechanical consequences of hypercholesterolemia and hyperlipidemia seem to 
differ, despite similar mechanistic outcomes. Upon evaluation of wall mechanics and 
microvessel density, the ApoE model has also been associated with profound microvessel 
rarefaction, marked by increases in TNF-α and thromboxane A2 (TxA2) while the LDLR mouse 
is portrays significant wall remodeling accompanied by an increase in monocyte chemotactic 
protein-1 (MCP-1) (92).    
Hypercholesterolemia and Inflammation 
Numerous studies have clearly established that hypercholesterolemia leads to an 
inflammatory response within the microvasculature, reflected by endothelial cell activation, 
leukocyte recruitment, rolling and adherence, as well as platelet activation and adhesion (84; 95).  
The decreased bioavailability of NO in hypercholesterolemia also diminishes the anti-
inflammatory properties of the endothelial cell, permitting the activity of growth factors on the 
cell surface and platelet activation to act as chemoattractants to a parade of inflammatory events. 
Leukocytes begin to roll along the lumen and adhere to the cell wall, extravasate, and reside 
within the intimal space (13).  Monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8) 
have both been found to be important in hypercholesterolemic patients, acting to increase 
monocyte recruitment and adherence which leads to wall remodeling (15; 64; 67; 92). 
Macrophages, derived from monocytes, begin to accumulate LDL and oxidized LDL (oxLDL) 
which develop into foam cells between the basal lamina of the endothelium and the smooth 
muscle layer (20). These foam cells lead to the production of numerous inflammatory and 
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oxidative stress markers, cytokines, chemokines, and growth factors which aggravate the balance 
of endothelial equilibrium leading to vascular dysfunction.   
Elevated cholesterol has also been shown to trigger the release of the inflammatory 
mediator C-reactive protein (CRP), a useful clinical marker of CVD (33; 98). It is hypothesized 
that CRP, via IL-6, may exacerbate vascular dysfunction by inhibiting eNOS, stimulating 
production of reactive oxygen species and increasing vascular permeability, and may also initiate 
the expression and stimulation of adhesion molecules, chemokine production, and thrombus 
formation within endothelial cells (67). Unfortunately, as a cellular marker of vascular 
inflammation, the source of CRP within the hypercholesterolemic condition is unclear (12).  
Hypercholesterolemia and Oxidative Stress 
 Excess oxidative stress is caused by an imbalance between pro- and anti-oxidant 
enzymes, leading to an overproduction of free radicals, including  superoxide, hydroxyl radicals, 
and lipid radicals, which may damage cellular components, interfering with normal function.  
Other molecules such as peroxynitrite, hydrogen peroxide, and hypochlorous acid are also 
oxidants, but are not considered free radicals. The two major sources of reactive oxidant species 
(ROS) within the vasculature are leukocytes (macrophages) recruited due to an endothelial injury 
signal and inefficiencies within smooth muscle cell mitochondrial metabolism (32).  
Hypercholesterolemia may also increase activity of three major oxidant producing 
enzyme systems; NADPH oxidases (NOX), xanthine oxidase, and myeloperoxidase (MPO). 
NOX acts to transfer an electron to an oxygen molecule, forming superoxide or H2O2 (14). While 
seven NOX isoforms have been identified (NOX1-5, DUOX 1 and 2), four of these (NOX1, 2, 4, 
and 5) have been recognized within the vascular wall, with NOX2 responsible for the greatest 
impact on ROS-related decreases to NO bioavailability (85). Xanthine oxidase forms superoxide 
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and H2O2 during the reduction of oxygen, while myeloperoxidase is produced by neutrophils and 
monocytes and produces a toxic hypochlorous acid; within a pathological condition overactive 
enzymes can lead to the overproduction these radicals, leading to scavenging of NO molecules, 
uncoupling of eNOS, and/or the formation of peroxynitrite (32). MPO is an enzyme produced by 
neutrophils and monocytes using hydrogen peroxide to produce hypochlorous acid. Additionally, 
eNOS uncoupling and substrate reduction (tetrahydrobiopterin (BH4) and L-arginine), can 
transform eNOS into a superoxide generating enzyme which can, in turn, produce greater 
amounts of oxidant radicals and hydrogen peroxide in addition to NO production (23; 66). 
 Evaluating the nitrotyrosine levels within the system will give insight to the amount of 
peroxynitrite formation, reductions in NO bioavailability, and the nitrosylation of protein 
tyrosines leading to oxidant radical formation and susbsequent oxidation. However, 
cholortyrosine will indicate MPO activity. While, evaluating the concentration of isoprostanes 
will indicate the amount of lipid peroxidation within the system; this is a systemic measurement 
and the molecules measure are not directly responsible for the endothelial cell activation as they 
are freely circulating throughout the blood, but may indicate a propensity of lipid peroxidation 
within the system.       
A range of antioxidant mechanisms are in place to minimize the balance of the effects of 
ROS, including superoxide dismutase (SOD), glutathione peroxidase (GPx4), catalase, and 
thioredoxin reductase. SOD, which comes in three forms, soluble cytoplasmic (SOD1), 
extracellular (SOD3) containing copper and zinc and mitochondrial (SOD2), containing 
manganese. SOD2 is the main cellular antioxidant system in all cell types is capable of 
converting superoxide radicals to H2O2 and oxygen (98).  GPx4 reduces H2O2 and lipid 
peroxides to water and lipid alcohols, and reduces the development of atherosclerosis during 
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hypercholesterolemia through the inhibition of lipid peroxidation and a decreased sensitivity of 
endothelial cells to oxidized lipids (31). Catalase acts to reduce hydrogen peroxide to oxygen 
molecules and water.  Within the pathological state of hypercholesterolemia, antioxidant systems 
are unable to handle the increased demand and the ROS production exceeds capacity. 
Thioredoxin reductase acts to enhance other antioxidant activity by recycling reducing agents. 
Within hypercholesterolemia, reactions between radicals and lipoproteins can lead to 
production of lipid radicals or oxLDL which can accumulate within the cellular membrane, 
disrupting normal cellular function and ultimately leading to poor vascular function (11; 43).  
The increased lipid radicals within hypercholesterolemia can, impact endothelium-dependent 
dilation through a reduced bioavailability of NO (11).  This conclusion is further supported with 
evidence that cholesterol fed animals treated with polyethylene-glycolated–SOD demonstrate an 
improved endothelium dependent dilation, while normocholesterolemic animals did not show 
any effects (63).  OxLDL can interact directly with the endothelial cell through interactions with 
the lectin-like oxLDL receptor (LOX-1), an endothelial receptor for oxidized LDL in endothelial 
cells (83). This receptor is induced by a variety of inflammatory cytokines, oxidative stress, 
hemodynamic changes, and abundance of ox-LDL (83).  Interactions with oxLDL causes further 
injury to the endothelial cell subsequently activating platelets signaling a variety of adhesion and 
inflammatory molecules including MCP-1. In addition to oxLDL, LOX-1 can bind advanced 
glycation end products (AGE), activated platelets, and leukocytes all furthering inflammatory 
and oxidative processes (83). 
Hypercholesterolemia and Pharmaceutical Therapies  
Statins, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors, are 
currently one of the most widely prescribed drugs on the market today. They target liver HMG 
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CoA reductase activity and inhibit the production of a cholesterol precursor, mevalonic acid. 
They also specifically act to change the conformation of HMG-CoA reductase when bound, 
preventing a functional structure (91). This enzymatic inhibition acts to prevent protease 
activation of sterol regulatory element binding proteins (SREBPs) from the endoplasmic 
reticulum, thereby preventing nuclear translocation and upregulation of LDL gene expression, 
limiting hepatic cholesterol production (91).  
Statins have been identified to have numerous positive outcomes associated with their 
direct cholesterol lowering (48; 54; 56; 69).  In addition to these, vasculoprotective properties 
such as increased NO bioavailability, antioxidant, anti-inflammatory and immunomodulatory 
properties leading to an overall improvement of endothelial function have also been identified; 
yet specifically identifying the discrete result in human hypercholesterolemic patients is difficult 
as the cholesterol lowering benefits are similar (41; 102).  These diverse positive vascular 
outcomes are most easily identified while using a genetically modified murine model, as the 
lipid-lowering results become null, leaving the pleiotropic effects evident.  While similar, these 
consequences independent of the cholesterol lowering effects include, but are not limited to, 
reducing inflammation, decreases in ROS, increases in NO bioavailability and endothelial 
function, decreases in platelet activation and aggregation, reduction in coagulation and decreases 
in cellular proliferation, among others (106). Additionally, statin therapy has been found to 
significantly improve endothelial function (based on flow-mediated dilator responses) in 
hypercholesterolemic patients who had also been diagnosed with PVD (30). While this beneficial 
effect may have resulted from an increased NO bioavailability, the underlying mechanisms have 
not been fully understood (51).  
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 Ezetimibe (Zetia) is a selective agent which acts to prevent cholesterol absorption in the 
intestine through targeting Niemann-Pick C1-like 1 protein (NPC1L1), which is expressed on the 
intestinal cell surface and is a transporter with secretion signal and sterol-sensing domains.  
Ezetimibe will inhibit this protein, thereby blocking LDL uptake from the intestine (61; 62). The 
subsequent reduction in cholesterol transport to the liver stimulates a compensatory increase in 
LDLR expression, thereby increasing vascular clearance with no serious side effects (38). While 
cholesterol lowering therapies have shown a positive correlation with reductions in 
cardiovascular events, ezetimibe has recently begun to show pleiotropic effects such as 
reductions in liver lipids, reductions in lipid lesions, reductions in ADMA levels, and increases 
in eNOS mRNA expression (20; 69). 
 When used in combination, ezetimibe and statins (e.g., Vytorin) act via complementary 
pathways to prevent cholesterol absorption from the intestine and hepatic production.  Long term 
co-administration of these drugs have been shown to reduce LDL blood cholesterol levels by 
60% while concurrently raising HDL levels and limiting liver toxicity, myotoxicity and/or 
rhabdomyolysis traditionally caused by statin treatment alone (17; 38; 82). However, at present, 
the side effects of the combined therapy are not well described, and it is unclear how effective 
these are for impacting the inflammatory and oxidative stress profiles (54; 56; 89). This class of 
drugs can only partially impact the cholesterol levels of patients diagnosed with familial 
hypercholesterolemia, as these patients lack the LDL receptor necessary for the uptake of the 
pharmaceutically reduced endogenous production and intestinal uptake of the available LDL.  
Oxidant Stress, Inflammation and Pharmaceutical Therapies 
 While lowering overall cholesterol levels can lead to a decrease in vascular oxidative 
stress and thereby improve endothelial function, some groups have found antioxidant properties 
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to be a pleiotropic effect of statins (100). When evaluated to examine NO in a biologically active 
form, cholesterol lowering drugs were shown to increase the efficiency of the NOS system, while 
simultaneously showing an inactivation of oxygen radicals within the system (44). These drugs 
may not act directly upon the radicals, but instead act to reduce oxidant stress by decreasing 
substrate availability for these radicals to act upon or by increasing antioxidant enzymatic 
activities, such as SOD (37). Statins have found to act upon the p21 Rac protein interrupting the 
NOX subunit assembly working directly to inhibit the production mechanism of superoxides 
through disruption of the NOX enzyme (104). Some studies have shown positive results with 
respect to lipid peroxidation, including the increase of an antioxidant effect leading to a decrease 
in ox-LDL with combination ezetimibe/statin treatment (39).  
Pharmaceutical treatments have been shown to influence inflammation through the 
decrease of systemic markers of inflammation and to increase the stability of existing plaques, 
thereby reducing the risk for thrombosis. Some groups are considering treating LDL as means to 
managing inflammation and preventing atherosclerotic lesions with mixed reviews and results 
(101; 111).  
CRP has been commonly used as a marker of inflammation in a clinical setting since it is 
associated with myocardial infarction and low-grade cardiovascular inflammation. Statin drugs 
have been shown to decrease CRP in numerous human studies, including JUPITER, ENHANCE, 
CARE, and PRINCE, regardless of their lipid lowering effects (81). Additional studies have 
shown an interference with the inflammatory process, impacting the expression of interleukins, 
adhesion molecules, platelet aggregation, and chemoattractants including IL-1, IL-6, IL-8, NF-
κB, and TNF-α culminating in the decrease of CRP (50).  
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Animal studies have shown atorvastatin to reduce inflammatory markers such as MCP-1 
and the activation of the nuclear factor NF-κB (10). More recently, as the pleiotropic effects of 
these interventions are being evaluated, some studies have found reductions in the adhesion 
molecules ICAM, VCAM, E-selectin, P-selectin, MMP-9, and platelet aggregation. These 
reductions are leading some to the conclusion that pharmaceutical therapies may reduce or limit 
the formation and instability of atherosclerotic plaques (16).  
Hypercholesterolemia and Exercise 
The AHA and American College of Sports Medicine (ACSM) have recently released 
joint guidelines recommending aerobic and resistance physical activities for individuals under 
the age of 65 to maintain health, reduce risk of chronic disease states, and manage current risk 
factors including hypercholesterolemia (34; 47; 94).  Hypercholesterolemia has been shown to 
impair aerobic capacity by impairing dilator regulation, thought to be due to a lack of vascular 
reactivity stemming from a reduction in NO bioavailability (57).  However, this decline in 
vascular reactivity may also be due to wall remodeling as seen in the LDLR mouse model of FH 
or poor blood flow distribution due to microvessel rarefaction seen in the ApoE mouse model of 
FCH (92). These may lead to a decrease in oxygen transport to working skeletal muscles during 
the hyperemic demand of exercise, further reducing aerobic capacity (57).  
Few groups examine dose-response relationships between exercise training and 
cholesterol adaptations. Some have suggested that exercise can alter blood lipids at low training 
volumes, although effects may not be significant until certain caloric thresholds are met. 
Exercise training has rarely been shown to have a direct effect on total cholesterol or LDL levels; 
however, significant increases in HDL and decreases in triglycerides have been identified (22).  
This may be a function of activity intensity, as a 1200 – 2200 kcal/week exercise program 
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performed at moderate intensities has been shown to reduce total and LDL cholesterol levels 
(22). 
A number of moderate-intensity exercise programs have shown improvements to 
systemic aerobic capacity, effectively reversing early stage hypercholesterolemic changes within 
the vasculature, including improved vascular reactivity, NO bioavailability and eNOS activity 
(28; 105). These increases in NO bioavailability in humans and animal models  of 
hypercholesterolemia have been attributed to eNOS expression and production of NO, due to a 
chronic rise in shear stress with exercise, as opposed to an increase in SOD or reduction in 
oxidant stress (19).  Exercise and shear stress have also been shown to improve mechanisms of 
endothelial vasodilation other than NO, such as prostaglandin release (93). Exercise has also 
been shown to ameliorate increases in inflammatory and oxidative stress markers during chronic 
disease state, which would benefit many low-grade inflammatory conditions (5).  
Oxidant Stress, Inflammation, and Exercise 
Cellular respiration and metabolism are directly linked to physical activity and exercise 
as they are the source responsible for muscle action. In the presence of oxygen, aerobic 
respiration allows for the production of ATP, where glucose is broken down to pyruvate and 
enters the mitochondria for further processing via Kreb’s cycle and oxidation via the electron 
transport chain.  Unfortunately,  minor inefficiencies within the mitochondria, including leaky 
membranes and limited cofactor availability, lead to a reduced ATP generation and the excess 
buildup of oxidants (80).    
In acute exercise alterations to the mitochondrial electron transport chain is a direct 
source of oxidant stress due to the significant amount of oxidative handling throughout the 
system (50). Therefore, any inefficiencies associated within this system are multiplied as 
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mitochondrial requirements increase due to an increase in activity, specifically during acute 
exercise when there is an increase in whole body oxygen consumption thereby increasing the 
generation of ROS by active tissues (7). During the production of these mitochondrial-derived 
radicals, there is also an increase of the pro-oxidant enzymes xanthine oxidase, myeloperoxidase, 
and NOX (42). The upregulation of these enzymes causes an increase in plasma markers of ROS, 
such as F2-isoprostanes (9).   This increased oxidant stress, while promoting negative 
cardiovascular effects, has recently been shown to occur in conjunction with increases in 
antibodies to ox-LDL and antioxidant enzymes (catalase) after one week of activity in mice (59). 
These changes suggest that after only a week of moderate activity, there is an initiation to 
improve hypercholesterolemia, limit the progression of foam cell development, and increase 
antioxidant enzyme activity within exercising and sedentary states.  As exercise persists, 
mitochondrial and antioxidant enzymes also improve; specifically, an increase in expression of 
Cu/Zn superoxide dismutase (SOD-1) and glutathione peroxidase lead to a higher oxidant 
handling capacity and contribution to improved function (19; 61). As a consequence, there is a 
decrease in the plasma markers of oxidative stress F2-isoprostane, myeloperoxidase, and 
malondialdehyde (86). Exercise training has also been shown to have a direct positive effect on 
the induction of eNOS and ecSOD (endothelial cell SOD), potent antioxidants. These increases 
are interdependent, as eNOS-/- mice seem to be unaffected an increase in ecSOD (24).  
Exercise and increases in NO have also been shown to induce HO-1 (heme oxygenase-1) 
expression. HO-1 products have similar anti-oxidant and anti-inflammatory effects, in addition to 
the inhibition of NF-KB an oxidant stress sensitive transcription factor (99). The inhibition of 
NF-kB leads to a decrease of the entire downstream signaling cascade, which could be the link to 
many of the NO-mediated anti-inflammatory effects observed with chronic exercise such as 
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decreases in leukocyte binding, chemotaxis, aggregation of platelets, and proliferation of smooth 
muscle cells (18).    
In the past, inflammation associated with physical activity has been described as the 
reaction to a number of repeated micro-traumas to the muscle (68). However, muscle has 
recently been identified as an endocrine organ, possessing the ability to  manufacture and release 
humoral mediators directly into the system in response to muscle contraction (72). This 
establishes a link between skeletal muscle activity and anti-inflammatory effects (70).  The 
cytokines produced, identified as myokines, include IL-6, IL-8, IL-15, brain-derived 
neurotrophic factor (BDNF), leukemia inhibitory factor (LIF) FGF21 and follistatin-like-1: each 
are regulated in some manner by the contraction or contractility of muscle (71). With respect to 
IL-6, the myokine hypothesis suggests that both type I and type II muscle fibers are capable of 
producing and releasing IL-6, which may act locally through AMPK signaling or systemically to 
improve hepatic glucose production and lipid metabolism (73).  
During acute exercise, there is an immediate increase in a variety of anti-inflammatory 
cytokines, such as IL-6, IL-1ra, sTNFR (soluble TNF-α receptor), and IL-10. However, pro-
inflammatory cytokines TNF-α (tumor necrosis factor- α) and IL-1 are generally not changed 
(74).   Chronic exercise leads to a reduction of systemic and local markers of inflammation 
within the vasculature has been well established within the literature (79). As exercise persists to 
a chronic state pro-inflammatory markers CRP, TNF-α, IFN-γ, MCP-1, IL-6, IL-8, and MMP-9 
have all been shown to decrease from initial baseline levels; whereas anti-inflammatory markers 
IL-10 and TGF-β increase indicating the development of a less inflammatory phenotype (53; 65). 
The timeline and exact mechanisms by which a chronic increase in activity will lead to modest 
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improvements in low-grade inflammation are uncertain (108). However, some groups are 
focusing on the “long-term anti-inflammatory effects of exercise” (65; 70). 
Conclusion 
Given the severity of hypercholesterolemia as a risk factor for the progression of negative 
CVD outcomes, the pathways of effective interventional strategies to manage cholesterol levels, 
improve vascular reactivity, and restore NO bioavailability warrant continued investment.  
Pharmaceutical therapies have presented a variety of vasculoprotective effects which are not 
fully understood, but involve a complex interaction between vascular signaling mechanisms, 
oxidant stress and chronic inflammation. Additionally, physical activity and exercise have long 
been suggested as means to modify CVD and manage cholesterol. Current evidence also 
supports the theory of a long term anti-inflammatory effects through modifications of the IL-6 
and CRP pathways, along with anti-oxidative effects of increased anti-oxidant enzyme 
expression and activity leading to a higher oxidant handling capacity at rest and during activity. 
These data suggest that the pleiotropic effects of exercise and conventional pharmaceutical 
therapies may be most beneficial when used in combination. 
Therefore, the purpose of this study was to investigate the condition of 
hypercholesterolemia and how it relates to mechanical adaptations to vascular reactivity, the 
altered mechanisms of endothelium dependent dilation, and the consequences of current 
clinically-relevant ameliorative therapies.  
 
 
 
 
 
 
 
 
16
 REFERENCES 
 
 
 1.  What Do My Cholesterol Levels Mean? American Heart Association . 2007. 6-22-2009.  
Ref Type: Internet Communication 
 2.  Aggarwal NT, Pfister SL and Campbell WB. Hypercholesterolemia enhances 15-
lipoxygenase-mediated vasorelaxation and acetylcholine-induced hypotension. 
Arterioscler Thromb Vasc Biol 28: 2209-2215, 2008. 
 3.  Aggarwal NT, Pfister SL, Gauthier KM, Chawengsub Y, Baker JE and Campbell 
WB. Chronic hypoxia enhances 15-lipoxygenase-mediated vasorelaxation in rabbit 
arteries. Am J Physiol Heart Circ Physiol 296: H678-H688, 2009. 
 4.  Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ and Hutten 
BA. A systematic review and meta-analysis of statin therapy in children with familial 
hypercholesterolemia. Arterioscler Thromb Vasc Biol 27: 1803-1810, 2007. 
 5.  Bai Y, Sigala W, Adams GR and Vaziri ND. Effect of exercise on cardiac tissue 
oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol 29: 213-
221, 2009. 
 6.  Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, 
Sourjina T, Peto R, Collins R and Simes R. Efficacy and safety of cholesterol-lowering 
treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised 
trials of statins. Lancet 366: 1267-1278, 2005. 
17
 7.  Bloomer RJ. Effect of exercise on oxidative stress biomarkers. Adv Clin Chem 46: 1-50, 
2008. 
 8.  Boodhwani M, Nakai Y, Mieno S, Voisine P, Bianchi C, Araujo EG, Feng J, Michael 
K, Li J and Sellke FW. Hypercholesterolemia impairs the myocardial angiogenic 
response in a swine model of chronic ischemia: role of endostatin and oxidative stress. 
Ann Thorac Surg 81: 634-641, 2006. 
 9.  Brennan ML, Penn MS, Van LF, Nambi V, Shishehbor MH, Aviles RJ, Goormastic 
M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE and Hazen SL. Prognostic value of 
myeloperoxidase in patients with chest pain. N Engl J Med 349: 1595-1604, 2003. 
 10.  Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F, Diaz C, 
Hernandez G and Egido J. HMG-CoA reductase inhibition by atorvastatin reduces 
neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32: 
2057-2064, 1998. 
 11.  Cai H and Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of 
oxidant stress. Circ Res 87: 840-844, 2000. 
 12.  Calabro P and Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol 20: 541-
546, 2005. 
18
 13.  Cannon RO, III. Role of nitric oxide in cardiovascular disease: focus on the 
endothelium. Clin Chem 44: 1809-1819, 1998. 
 14.  Cave A. Selective targeting of NADPH oxidase for cardiovascular protection. Curr Opin 
Pharmacol 9: 208-213, 2009. 
 15.  Choudhury RP, Fuster V and Fayad ZA. Molecular, cellular and functional imaging of 
atherothrombosis. Nat Rev Drug Discov 3: 913-925, 2004. 
 16.  Chung HK, Lee IK, Kang H, Suh JM, Kim H, Park KC, Kim DW, Kim YK, Ro HK 
and Shong M. Statin inhibits interferon-gamma-induced expression of intercellular 
adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol 
Med 34: 451-461, 2002. 
 17.  Cole P and Rabasseda X. Enhanced hypercholesterolemia therapy: the 
ezetimibe/simvastatin tablet. Drugs Today (Barc ) 41: 317-327, 2005. 
 18.  de Winther MP, Kanters E, Kraal G and Hofker MH. Nuclear factor kappaB 
signaling in atherogenesis. Arterioscler Thromb Vasc Biol 25: 904-914, 2005. 
 19.  de Moraes C, Davel AP, Rossoni LV, Antunes E and Zanesco A. Exercise training 
improves relaxation response and SOD-1 expression in aortic and mesenteric rings from 
high caloric diet-fed rats. BMC Physiol 8: 12, 2008. 
19
 20.  Dilaveris P, Giannopoulos G, Riga M, Synetos A and Stefanadis C. Beneficial effects 
of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 5: 227-
237, 2007. 
 21.  Drolet MC, Plante E, Battistini B, Couet J and Arsenault M. Early endothelial 
dysfunction in cholesterol-fed rabbits: a non-invasive in vivo ultrasound study. 
Cardiovasc Ultrasound 2: 10, 2004. 
 22.  Durstine JL, Grandjean PW, Davis PG, Ferguson MA, Alderson NL and DuBose 
KD. Blood lipid and lipoprotein adaptations to exercise: a quantitative analysis. Sports 
Med 31: 1033-1062, 2001. 
 23.  Forstermann U and Munzel T. Endothelial nitric oxide synthase in vascular disease: 
from marvel to menace. Circulation 113: 1708-1714, 2006. 
 24.  Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G and Harrison DG. 
Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise 
training. J Clin Invest 105: 1631-1639, 2000. 
 25.  Goldstein JL, Hobbs HH and Brown MS. Familial hypercholesterolemia. In: The 
metabolic and molecular bases of inherited diseases., edited by Scriver CR, Beaudet AL 
and Sly WS. New York: McGraw-Hill Book Co, 2001, p. 2863-2913. 
20
 26.  Goligorsky MS. Endothelial cell dysfunction: can't live with it, how to live without it. 
Am J Physiol Renal Physiol 288: F871-F880, 2005. 
 27.  Goodwill AG, Stapleton PA, James ME, d'Audiffret AC and Frisbee JC. Increased 
arachidonic acid-induced thromboxane generation impairs skeletal muscle arteriolar 
dilation with genetic dyslipidemia. Microcirculation 15: 621-631, 2008. 
 28.  Goto C, Nishioka K, Umemura T, Jitsuiki D, Sakagutchi A, Kawamura M, 
Chayama K, Yoshizumi M and Higashi Y. Acute moderate-intensity exercise induces 
vasodilation through an increase in nitric oxide bioavailiability in humans. Am J 
Hypertens 20: 825-830, 2007. 
 29.  Green DJ, Walsh JH, Maiorana A, Burke V, Taylor RR and O'Driscoll JG. 
Comparison of resistance and conduit vessel nitric oxide-mediated vascular function in 
vivo: effects of exercise training. J Appl Physiol 97: 749-755, 2004. 
 30.  Grodzinska L, Starzyk D, Bieron K, Goszcz A and Korbut R. Simvastatin effects in 
normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a 
pilot study. Basic Clin Pharmacol Toxicol 96: 413-419, 2005. 
 31.  Guo Z, Ran Q, Roberts LJ, Zhou L, Richardson A, Sharan C, Wu D and Yang H. 
Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in 
apolipoprotein E-deficient mice. Free Radic Biol Med 44: 343-352, 2008. 
21
 32.  Harrison DG. Endothelial function and oxidant stress. Clin Cardiol 20: II-7, 1997. 
 33.  Hashimoto H, Kitagawa K, Hougaku H, Shimizu Y, Sakaguchi M, Nagai Y, Iyama 
S, Yamanishi H, Matsumoto M and Hori M. C-reactive protein is an independent 
predictor of the rate of increase in early carotid atherosclerosis. Circulation 104: 63-67, 
2001. 
 34.  Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, 
Heath GW, Thompson PD and Bauman A. Physical activity and public health: updated 
recommendation for adults from the American College of Sports Medicine and the 
American Heart Association. Med Sci Sports Exerc 39: 1423-1434, 2007. 
 35.  Hayakawa H and Raij L. Relationship between hypercholesterolaemia, endothelial 
dysfunction and hypertension. J Hypertens 17: 611-619, 1999. 
 36.  Henderson KK, Turk JR, Rush JW and Laughlin MH. Endothelial function in 
coronary arterioles from pigs with early-stage coronary disease induced by high-fat, high-
cholesterol diet: effect of exercise. J Appl Physiol 97: 1159-1168, 2004. 
 37.  Hoffman R, Brook GJ and Aviram M. Hypolipidemic drugs reduce lipoprotein 
susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis 
93: 105-113, 1992. 
22
 38.  Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ and Hutten BA. 
Familial hypercholesterolemia: current treatment and advances in management. Expert 
Rev Cardiovasc Ther 6: 567-581, 2008. 
 39.  Hussein O, Minasian L, Itzkovich Y, Shestatski K, Solomon L and Zidan J. 
Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in 
hypercholesterolaemia as monotherapy or in addition to simvastatin. Br J Clin Pharmacol 
65: 637-645, 2008. 
 40.  Ingram DG, Newcomer SC, Price EM, Eklund KE, McAllister RM and Laughlin 
MH. Chronic nitric oxide synthase inhibition blunts endothelium-dependent function of 
conduit coronary arteries, not arterioles. Am J Physiol Heart Circ Physiol 292: H2798-
H2808, 2007. 
 41.  Jasinska M, Owczarek J and Orszulak-Michalak D. Statins: a new insight into their 
mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59: 483-499, 
2007. 
 42.  Ji LL. Antioxidants and oxidative stress in exercise. Proc Soc Exp Biol Med 222: 283-
292, 1999. 
 43.  Jiang F, Gibson AP and Dusting GJ. Endothelial dysfunction induced by oxidized low-
density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E 
deficient mice. Eur J Pharmacol 424: 141-149, 2001. 
23
 44.  Kalinowski L, Dobrucki LW, Brovkovych V and Malinski T. Increased nitric oxide 
bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. 
Circulation 105: 933-938, 2002. 
 45.  Kang J, Albadawi H, Patel VI, Abbruzzese TA, Yoo JH, Austen WG, Jr. and 
Watkins MT. Apolipoprotein E-/- mice have delayed skeletal muscle healing after hind 
limb ischemia-reperfusion. J Vasc Surg 48: 701-708, 2008. 
 46.  Kauser K, da Cunha V, Fitch R, Mallari C and Rubanyi GM. Role of endogenous 
nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am J 
Physiol Heart Circ Physiol 278: H1679-H1685, 2000. 
 47.  Kingwell BA. Nitric oxide-mediated metabolic regulation during exercise: effects of 
training in health and cardiovascular disease. FASEB J 14: 1685-1696, 2000. 
 48.  Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-
lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 49: 2003-
2009, 2007. 
 49.  Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, 
Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, 
Kita T and Narumiya S. Roles of thromboxane A(2) and prostacyclin in the 
development of atherosclerosis in apoE-deficient mice. J Clin Invest 114: 784-794, 2004. 
24
 50.  Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las HN, Cachofeiro V and 
Luno J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: 
beneficial effects of statins. Curr Med Chem 14: 243-248, 2007. 
 51.  Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin 
Pharmacol 58: 719-731, 2003. 
 52.  Leigh SE, Foster AH, Whittall RA, Hubbart CS and Humphries SE. Update and 
analysis of the University College London low density lipoprotein receptor familial 
hypercholesterolemia database. Ann Hum Genet 72: 485-498, 2008. 
 53.  Lemos ET, Reis F, Baptista S, Pinto R, Sepodes B, Vala H, Rocha-Pereira P, Silva 
GC, Teixeira N, Silva AS, Carvalho L, Teixeira F and Das UN. Exercise training 
decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition 2008. 
 54.  Liu PY, Liu YW, Lin LJ, Chen JH and Liao JK. Evidence for statin pleiotropy in 
humans: differential effects of statins and ezetimibe on rho-associated coiled-coil 
containing protein kinase activity, endothelial function, and inflammation. Circulation 
119: 131-138, 2009. 
 55.  Lloyd-Jones D, Adams R, Carnethon M, De SG, Ferguson TB, Flegal K, Ford E, 
Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, 
Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian 
D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, 
25
Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J and Hong 
Y. Heart disease and stroke statistics--2009 update: a report from the American Heart 
Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119: 
e21-181, 2009. 
 56.  Maki-Petaja KM, Booth AD, Hall FC, Wallace SM, Brown J, McEniery CM and 
Wilkinson IB. Ezetimibe and simvastatin reduce inflammation, disease activity, and 
aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll 
Cardiol 50: 852-858, 2007. 
 57.  Maxwell AJ, Schauble E, Bernstein D and Cooke JP. Limb blood flow during exercise 
is dependent on nitric oxide. Circulation 98: 369-374, 1998. 
 58.  McNeely MJ, Edwards KL, Marcovina SM, Brunzell JD, Motulsky AG and Austin 
MA. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: 
a 20-year prospective study. Atherosclerosis 159: 471-481, 2001. 
 59.  Meilhac O, Ramachandran S, Chiang K, Santanam N and Parthasarathy S. Role of 
arterial wall antioxidant defense in beneficial effects of exercise on atherosclerosis in 
mice. Arterioscler Thromb Vasc Biol 21: 1681-1688, 2001. 
 60.  Mietus-Snyder M and Malloy MJ. Endothelial dysfunction occurs in children with two 
genetic hyperlipidemias: improvement with antioxidant vitamin therapy. J Pediatr 133: 
35-40, 1998. 
26
 61.  Mignini F, Tomassoni D, Traini E and Streccioni V. Antioxidant endogenous defense 
in a human model of physical stress. Clin Exp Hypertens 30: 776-784, 2008. 
 62.  Miura S and Saku K. Ezetimibe, a selective inhibitor of the transport of cholesterol. 
Intern Med 47: 1165-1170, 2008. 
 63.  Mugge A, Elwell JH, Peterson TE, Hofmeyer TG, Heistad DD and Harrison DG. 
Chronic treatment with polyethylene-glycolated superoxide dismutase partially restores 
endothelium-dependent vascular relaxations in cholesterol-fed rabbits. Circ Res 69: 1293-
1300, 1991. 
 64.  Nelken NA, Coughlin SR, Gordon D and Wilcox JN. Monocyte chemoattractant 
protein-1 in human atheromatous plaques. J Clin Invest 88: 1121-1127, 1991. 
 65.  Oberbach A, Lehmann S, Kirsch K, Krist J, Sonnabend M, Linke A, Tonjes A, 
Stumvoll M, Bluher M and Kovacs P. Long-term exercise training decreases 
interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of 
the -174G/C variant in IL-6 gene. Eur J Endocrinol 159: 129-136, 2008. 
 66.  Ogita H and Liao J. Endothelial function and oxidative stress. Endothelium 11: 123-
132, 2004. 
27
 67.  Pasceri V, Cheng JS, Willerson JT and Yeh ET. Modulation of C-reactive protein-
mediated monocyte chemoattractant protein-1 induction in human endothelial cells by 
anti-atherosclerosis drugs. Circulation 103: 2531-2534, 2001. 
 68.  Peake J, Nosaka K and Suzuki K. Characterization of inflammatory responses to 
eccentric exercise in humans. Exerc Immunol Rev 11: 64-85, 2005. 
 69.  Pearson TA, Ballantyne CM, Veltri E, Shah A, Bird S, Lin J, Rosenberg E and 
Tershakovec AM. Pooled analyses of effects on C-reactive protein and low density 
lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or 
ezetimibe added to baseline statin therapy. Am J Cardiol 103: 369-374, 2009. 
 70.  Pedersen BK. The diseasome of physical inactivity--and the role of myokines in muscle-
-fat cross talk. J Physiol 587: 5559-5568, 2009. 
 71.  Pedersen BK, Akerstrom TC, Nielsen AR and Fischer CP. Role of myokines in 
exercise and metabolism. J Appl Physiol 103: 1093-1098, 2007. 
 72.  Pedersen BK and Febbraio MA. Muscle as an endocrine organ: focus on muscle-
derived interleukin-6. Physiol Rev 88: 1379-1406, 2008. 
 73.  Pedersen BK and Fischer CP. Physiological roles of muscle-derived interleukin-6 in 
response to exercise. Curr Opin Clin Nutr Metab Care 10: 265-271, 2007. 
28
 74.  Pedersen BK and Hoffman-Goetz L. Exercise and the immune system: regulation, 
integration, and adaptation. Physiol Rev 80: 1055-1081, 2000. 
 75.  Pfister SL. Characterization of endothelial thromboxane receptors in rabbit aorta. 
Prostaglandins Other Lipid Mediat 87: 54-61, 2008. 
 76.  Pfister SL. Aortic thromboxane receptor deficiency alters vascular reactivity in 
cholesterol-fed rabbits. Atherosclerosis 189: 358-363, 2006. 
 77.  Pfister SL, Falck JR and Campbell WB. Enhanced synthesis of epoxyeicosatrienoic 
acids by cholesterol-fed rabbit aorta. Am J Physiol 261: H843-H852, 1991. 
 78.  Pfister SL, Spitzbarth N, Edgemond W and Campbell WB. Vasorelaxation by an 
endothelium-derived metabolite of arachidonic acid. Am J Physiol 270: H1021-H1030, 
1996. 
 79.  Reese EP. Arthritis; the use of physical therapy as an aspect of management. Calif Med 
89: 204-209, 1958. 
 80.  Rich PR. The molecular machinery of Keilin's respiratory chain. Biochem Soc Trans 31: 
1095-1105, 2003. 
29
 81.  Ridker PM, Rifai N, Pfeffer MA, Sacks F and Braunwald E. Long-term effects of 
pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent 
Events (CARE) Investigators. Circulation 100: 230-235, 1999. 
 82.  Robinson JG and Davidson MH. Combination therapy with ezetimibe and simvastatin 
to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 4: 461-476, 2006. 
 83.  Sakurai K and Sawamura T. Stress and vascular responses: endothelial dysfunction via 
lectin-like oxidized low-density lipoprotein receptor-1: close relationships with oxidative 
stress. J Pharmacol Sci 91: 182-186, 2003. 
 84.  Scalia R, Appel JZ, III and Lefer AM. Leukocyte-endothelium interaction during the 
early stages of hypercholesterolemia in the rabbit: role of P-selectin, ICAM-1, and 
VCAM-1. Arterioscler Thromb Vasc Biol 18: 1093-1100, 1998. 
 85.  Schulz E and Munzel T. NOX5, a new "radical" player in human atherosclerosis? J Am 
Coll Cardiol 52: 1810-1812, 2008. 
 86.  Seals DR, Desouza CA, Donato AJ and Tanaka H. Habitual exercise and arterial 
aging. J Appl Physiol 105: 1323-1332, 2008. 
 87.  Segrest JP. The role of non-LDL:non-HDL particles in atherosclerosis. Curr Diab Rep 2: 
282-288, 2002. 
30
 88.  Selvin E and Erlinger TP. Prevalence of and risk factors for peripheral arterial disease 
in the United States: results from the National Health and Nutrition Examination Survey, 
1999-2000. Circulation 110: 738-743, 2004. 
 89.  Sirvent P, Mercier J and Lacampagne A. New insights into mechanisms of statin-
associated myotoxicity. Curr Opin Pharmacol 8: 333-338, 2008. 
 90.  Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ and 
Deanfield JE. Impairment of endothelium-dependent dilation is an early event in 
children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J 
Clin Invest 93: 50-55, 1994. 
 91.  Stancu C and Sima A. Statins: mechanism of action and effects. J Cell Mol Med 5: 378-
387, 2001. 
 92.  Stapleton PA, Goodwill AG, James ME, d'Audiffret AC and Frisbee JC. Differential 
impact of familial hypercholesterolemia and combined hyperlipidemia on vascular wall 
and network remodeling in mice. Microcirculation 17: 47-58, 2010. 
 93.  Stapleton PA, Goodwill AG, James ME and Frisbee JC. Altered mechanisms of 
endothelium-dependent dilation in skeletal muscle arterioles with genetic 
hypercholesterolemia. Am J Physiol Regul Integr Comp Physiol 293: R1110-R1119, 
2007. 
31
 94.  Stefanick ML, Mackey S, Sheehan M, Ellsworth N, Haskell WL and Wood PD. 
Effects of diet and exercise in men and postmenopausal women with low levels of HDL 
cholesterol and high levels of LDL cholesterol. N Engl J Med 339: 12-20, 1998. 
 95.  Stokes KY, Calahan L, Russell JM, Gurwara S and Granger DN. Role of platelets in 
hypercholesterolemia-induced leukocyte recruitment and arteriolar dysfunction. 
Microcirculation 13: 377-388, 2006. 
 96.  Stokes KY, Cooper D, Tailor A and Granger DN. Hypercholesterolemia promotes 
inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free 
Radic Biol Med 33: 1026-1036, 2002. 
 97.  Stokes KY, Russell JM, Jennings MH, Alexander JS and Granger DN. Platelet-
associated NAD(P)H oxidase contributes to the thrombogenic phenotype induced by 
hypercholesterolemia. Free Radic Biol Med 43: 22-30, 2007. 
 98.  Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G and Luscher TF. 
Protection of endothelial function: targets for nutritional and pharmacological 
interventions. J Cardiovasc Pharmacol 47 Suppl 2: S136-S150, 2006. 
 99.  Sun MW, Zhong MF, Gu J, Qian FL, Gu JZ and Chen H. Effects of different levels 
of exercise volume on endothelium-dependent vasodilation: roles of nitric oxide synthase 
and heme oxygenase. Hypertens Res 31: 805-816, 2008. 
32
 100.  Takemoto M and Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme 
a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001. 
 101.  Tuzcu EM and Nicholls SJ. Statins targeting inflammation by lowering low-density 
lipoprotein? J Am Coll Cardiol 49: 2010-2012, 2007. 
 102.  Vlachopoulos C, Aznaouridis K, Dagre A, Vasiliadou C, Masoura C, Stefanadi E, 
Skoumas J, Pitsavos C and Stefanadis C. Protective effect of atorvastatin on acute 
systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic 
subjects. Eur Heart J 28: 2102-2109, 2007. 
 103.  Vladimirova-Kitova L, Deneva T, Angelova E, Nikolov F, Marinov B and Mateva N. 
Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects 
with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging 28: 417-
425, 2008. 
 104.  Wagner AH, Kohler T, Ruckschloss U, Just I and Hecker M. Improvement of nitric 
oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of 
endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69, 2000. 
 105.  Walsh JH, Yong G, Cheetham C, Watts GF, O'Driscoll GJ, Taylor RR and Green 
DJ. Effects of exercise training on conduit and resistance vessel function in treated and 
untreated hypercholesterolaemic subjects. Eur Heart J 24: 1681-1689, 2003. 
33
 106.  Wassmann S and Nickenig G. Interrelationship of free oxygen radicals and endothelial 
dysfunction--modulation by statins. Endothelium 10: 23-33, 2003. 
 107.  White CR, Parks DA, Patel RP, Shelton J, Tarpey MM, Freeman BA and rley-
Usmar VM. L-Arginine inhibits xanthine oxidase-dependent endothelial dysfunction in 
hypercholesterolemia. FEBS Lett 561: 94-98, 2004. 
 108.  Wilund KR. Is the anti-inflammatory effect of regular exercise responsible for reduced 
cardiovascular disease? Clin Sci (Lond) 112: 543-555, 2007. 
 109.  Wolfle SE and de Wit C. Intact endothelium-dependent dilation and conducted 
responses in resistance vessels of hypercholesterolemic mice in vivo. J Vasc Res 42: 475-
482, 2005. 
 110.  Woodman CR, Ingram D, Bonagura J and Laughlin MH. Exercise training improves 
femoral artery blood flow responses to endothelium-dependent dilators in 
hypercholesterolemic pigs. Am J Physiol Heart Circ Physiol 290: H2362-H2368, 2006. 
 111.  Yusuf S, Lonn E and Bosch J. Lipid lowering for primary prevention. Lancet 373: 
1152-1155, 2009. 
 
 
34
  
 
 
 
 
 
DIFFERENTIAL IMPACT OF FAMILIAL HYPERCHOLESTEROLEMIA AND COMBINED 
HYPERLIPIDEMIA ON VASCULAR WALL AND NETWORK REMODELING IN MICE 
 
 
Phoebe A. Stapleton1,2, Adam G. Goodwill1,3, Milinda E. James1,3,  
Alexandre C. d’Audiffret1,4 and Jefferson C. Frisbee1,3 
 
 
Center for Cardiovascular and Respiratory Sciences1, Division of Exercise Physiology2, Department of 
Physiology and Pharmacology3, and Division of Vascular and Endovascular Surgery4 
West Virginia University School of Medicine, Morgantown, WV 26506 
 
 
 
Running Head: Dyslipidemia and vascular remodeling  
 
 
 
 
 
 
 
 
35
Dyslipidemia and vascular remodeling 
 
ABSTRACT 
Genetic familial hypercholesterolemia (FH) and combined hyperlipidemia (FCH) are characterized by elevated 
plasma LDL (FH) and LDL/triglycerides (FCH), with mouse models represented by LDL receptor (LDLR) and 
apolipoprotein E (ApoE) gene deletion mice, respectively.  Given the impact of FH and FCH on health 
outcomes, we determined the impact of FH/FCH on vascular structure in LDLR and ApoE mice.  LDLR, ApoE 
and control mice were utilized at 12-13 and 22-23 weeks when gracilis arteries were studied for wall mechanics 
and gastrocnemius muscles were harvested for microvessel density measurements.  Conduit arteries and plasma 
samples were harvested for biochemical analyses.  Arteries from ApoE and LDLR exhibited blunted expansion 
versus control, reduced distensibility and left-shifted stress versus strain relation (LDLR>ApoE).  Microvessel 
density was reduced in ApoE and LDLR (ApoE>LDLR).  Secondary analyses suggested that wall remodeling 
in LDLR was associated with cholesterol and MCP-1, while rarefaction in ApoE was associated with TNF-α, 
triglycerides and vascular production of TxA2.  Remodeling in ApoE and LDLR appears distinct; as that in 
LDLR is preferential for vascular walls, while that for ApoE is stronger for rarefaction.  Remodeling in LDLR 
may be associated with cellular adhesion, while that in ApoE may be associated with pro-apoptotsis and 
constrictor prostanoid generation.    
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INTRODUCTION 
 Numerous previous studies have determined that severe dyslipidemia, including both hypercholesterolemia 
and hypertriglyceridemia represent significant risk factors for the development of peripheral artery diseases and 
negative health outcomes (10, 13, 15, 23, 31).  Overwhelmingly, these address alterations to patterns of 
atherosclerotic plaque, lesion and fatty streak depositions within the vascular lumen, the propensity for the creation 
of emboli, the contribution to occlusive disease states, and downstream tissue/organ outcomes (3, 15, 20, 39).  
While unquestionably of considerable clinical significance, these overt pathological states do not provide a complete 
understanding of the alterations to vascular structure and function that accompany dyslipidemia.   
 We have recently determined that in two mouse models of genetic dyslipidemia on the C57/Bl6/J 
background, the low density lipoprotein receptor gene deletion (B6.129S7-Ldlrtm1Her/J; LDLR) and the 
apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) the patterns of endothelium-dependent arteriolar 
reactivity are significantly altered from their control strains (C57; refs: 18, 40).  In terms of clinical relevance, 
the LDLR mouse represents a model of familial hypercholesterolemia (FH; refs: 27, 37), characterized by 
striking elevations in plasma LDL levels, while the ApoE mouse represents familial combined hyperlipidemia 
(FCH; refs: 35, 36, 45), characterized by elevated plasma LDL (although not to levels in FH) and triglycerides.  
Specifically, both the LDLR and ApoE mouse models exhibit a striking loss of vascular nitric oxide 
bioavailability, as demonstrated by vascular responses to nitric oxide-dependent stimuli (11, 40, 41, 44).   
However, this is more complicated than a simple loss of NO bioavailability.  Previous studies in our laboratory 
(40) and by others (1) have suggested that this loss of NO bioavailability may be partially compensated for 
through alterations to arachidonic acid metabolism via lipoxygenases.  Further, other reports exist suggesting 
that there may also be an additional shift in arachidonic acid metabolism with hypercholesterolemia, increasing 
the production of thromboxane A2 (TxA2) versus prostacyclin (PGI2) which also has the potential to negatively 
impact vascular function (18, 25).  Finally, taken in combination with recent work from Wolfle and de Wit, 
suggesting that conducted responses in microvessels of LDLR mice were largely intact (43), and from Pfister et 
37
Dyslipidemia and vascular remodeling 
 
al. indicating an alteration in arachidonic acid metabolism in vascular tissue from hypercholesterolemic rabbits 
(34), and it becomes clear that the net vascular outcomes from dyslipidemia can be very complicated.   
 From the perspective of vascular outcomes and the determination of tissue perfusion, one area that 
requires further attention is that of the vascular remodeling that accompanies genetic dyslipidemia, and this 
should incorporate two different elements of remodeling; vascular wall mechanics and microvessel network 
structure.  While studies exist which describe wall stiffening with genetic dyslipidemia (2, 7, 16), these are 
limited by the analyses utilized and do not provide for a more thorough understanding.  Additionally, the study 
of microvessel density under conditions of dyslipidemia has been extremely limited, although what evidence is 
available suggests that this may be reduced with hypercholesterolemia (9, 24). 
 The purpose of the present study was to determine differences in skeletal muscle microvascular 
remodeling (i.e., resistance artery wall mechanics and microvessel density) under conditions of FH and FCH 
utilizing the LDLR and ApoE mouse models of these conditions.  The current study was designed to test the 
hypothesis that the progression of FH and FCH, while causing a remodeling of the skeletal muscle vasculature 
in both conditions, will be distinct in their vascular outcomes owing to differences in lipid and inflammatory 
profiles and impacts on endothelial function.  This study will not only provide information regarding relevant 
changes to two key indices of vascular structure, it will also evaluate the temporal development of these 
alterations, involving mice at 12-13 and 22-23 weeks of age.  Finally, these results are compared with an 
extensive analysis of biomarkers between the three strains to determine if differences in outcomes may be 
associated with a specific clustering of contributing elements.  It is believed that this process may provide a 
framework for targeted interventional procedures to ameliorate the poor vascular outcomes associated with 
genetic dyslipidemia. 
MATERIALS AND METHODS 
Animals:  This study utilized three strains of mice; C57/Bl6/J as the controls, and the LDLR and ApoE mice as 
models of FH and FCH, respectively.  All mice were purchased from Jackson Laboratories (Bar Harbor, ME).  
Male mice of each strain were fed standard chow and drinking water ad libitum and were housed in the animal care 
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facility at the West Virginia University Health Sciences Center and all protocols received prior IACUC approval.  
At 12-13 or 22-23 weeks of age, mice were anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.), 
and received tracheal intubation to facilitate maintenance of a patent airway.  In all mice, a carotid artery was 
cannulated for determination of arterial pressure.  After surgical removal of gracilis muscle resistance arteries (see 
below), deeply anesthetized mice received a bilateral pneumothoracotomy followed by cardiac puncture, wherein 
venous blood aliquots were drawn into tubes containing either heparin (for lipid determination) or K2-EDTA (for all 
other analyses).  Samples were immediately frozen in liquid N2 and processed as batches for lipid profiles (Wako) 
and inflammatory markers (Millipore) using commercially available kits.   
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the right gracilis artery 
was removed, cannulated, and extended to its approximate in situ length (14).  Following equilibration, the 
perfusate and superfusate were replaced with Ca2+-free physiological salt solution and vessels were treated with 
10-7 M phenylephrine until all tone was abolished.  Subsequently, intralumenal pressure was altered, in 20 
mmHg increments, between 0 mmHg and 160 mmHg and the inner and outer diameter of arteries was 
determined at each pressure.  To ensure that a negative intralumenal pressure was not exerted on the vessel, 5 
mmHg was used as the “0 mmHg” intralumenal pressure point; all other values of intralumenal pressure were 
multiples of 20 mmHg up to 160 mmHg.  Specific pressures were randomized to prevent the occurrence of 
ordering effects.  After 10 minutes at each intralumenal pressure, the inner and outer diameter of the passive 
arteriole was determined.  These data were used to calculate arteriolar wall mechanics which were used as 
indicators of structural alterations to individual microvessels (19).  Vesse wall thickness was calculated as: 
( )
2
IDODWT −=  
where WT represents wall thickness (μm) and OD and ID represent arteriolar outer and inner diameter, 
respectively (μm).  Arteriolar cross-sectional wall area (CSWA; μm2), assuming the arteriole is cross-
sectionally round, is calculated as: 
( ) ( ) ⎥⎦⎤⎢⎣⎡−⎥⎦⎤⎢⎣⎡= 22 22 IDODCWSA ππ  
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Incremental arteriolar distensibility (DISTINC; % change in arteriolar diameter/mmHg) was calculated 
as: 
( ) 100×⎟⎠⎞⎜⎝⎛ Δ×Δ= ILiINC PIDIDDIST  
where ΔID represents the change in internal arteriolar diameter for each incremental change in intralumenal 
pressure (ΔPIL), and IDi represents the initial internal diameter prior to the pressure change.   
 Circumferential wall stress is a measure of the average amount of distending force (in this case pressure; 
expressed in N/m2) exerted on a deformable object.  For the calculation of circumferential stress, intralumenal 
pressure was converted from mmHg to N/m2, where 1 mmHg=1.334×102 N/m2.  Circumferential stress (σ) was 
then calculated as: 
( )( )WTIDPIL 2×=σ  
Circumferential strain is a measurement of the degree of deformation exhibited by an object (in this case 
the vessel wall) as a result of the imposed stress. Circumferential strain (ε) was calculated as: 
( )
5
5
ID
IDID −=ε  
where ID5 represents the internal arteriolar diameter at the lowest intralumenal pressure (i.e., 5 mmHg). 
 The tangential elastic modulus (ET) describes an object’s tendency to be deformed elastically in 
response to an applied stress.   A vessel’s ET is defined as the slope of its circumferential stress versus strain 
relation. To determine tangential elastic modulus (ET), the stress versus strain curves from each vessel were fit 
(OLS, r2>0.85) with the following exponential equation: 
βεσσ e5=  
where σ5 represents circumferential stress at ID5 and β is the slope coefficient, which will be a function of the 
independent variable, ε.  ET was then estimated at different values of circumferential stress from the derivative 
of the exponential curve:  
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βεβσεσ eddET 5==  
Determination of Microvessel Density:  While under anesthesia, the right gastrocnemius muscle from each 
mouse was removed, rinsed in physiological salt solution and lightly fixed in 0.25% formalin.  Muscles were 
embedded in paraffin and cut into 5 μm cross sections, which were stained with Griffonia simplicifolia I lectin 
(Sigma), and mounted on microscope slides, as described previously (14).  Using epifluorescence microscopy, 
localization of labeled microvessels was performed with a Nikon E600 upright microscope with a 20x objective 
lens (Plan Fluo phase NA 0.5).  Excitation was provided by a 75 watt Xenon Arc lamp through a Lambda 10-2 
optical filter changer (Sutter Instrument Company, Novato, CA) controlling a 595nm excitation filter and a 615 
nm emission filter.  All acquired images from individual sections were analyzed for number of microvessels and 
number of skeletal muscle fibers using commercially available software. 
Measurement of Vascular Nitric Oxide Bioavailability: From each mouse, the aorta was removed and vascular 
nitric oxide production was assessed using amperometric sensors (World Precision Instruments).  Briefly, 
aortae were sectioned longitudinally, pinned in a silastic coated dish and superfused with warmed (37°C) 
physiological salt solution equilibrated with 95% O2/5% CO2.  The nitric oxide sensor (ISO-NOPF 100) was 
placed in close apposition to the endothelial surface and a baseline level of current was obtained.  Subsequently, 
aortae were exposed to acute challenge with methacholine (10-6 M) and changes in current were determined.  To 
verify that recorded data represented nitric oxide release, responses were re-evaluated following acute treatment 
of aortae with L-NAME (10-4 M).  
Determination of Vascular Metabolites of Arachidonic Acid:  Vascular production of 6-keto-prostaglandin F1α (6-
keto-PGF1α; the stable breakdown product of PGI2; ref. 32), and 11-dehydro-thromboxane B2 (11-dehydro-TxB2; 
the stable breakdown product of TxA2; ref. 8) in response to challenge with arachidonic acid within the three mouse 
strains was assessed using pooled conduit arteries (femoral, saphenous, iliac, carotid arteries) from each mouse.  
Vessels were incubated in microcentrifuge tubes in 1 ml of physiological salt solution for 30 minutes under control 
conditions (21% O2), after which time arachidonic acid (10-5 M) was added to the tube for an additional 30 minutes.  
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After the second 30 minute period, the solution was transferred to a new tube, frozen in liquid N2 and stored at -
80°C.  Metabolite release by the vessels was determined using commercially available kits for 6-keto-PGF1α and 
11-dehydro-TxB2 (Cayman). 
Statistical Analyses:  All data are presented as mean±SEM.  Differences in passive mechanical characteristics and 
microvessel density between mouse strains were assessed using analysis of variance (ANOVA) or regression 
analyses, with Student-Newman-Keuls-test post-hoc, as appropriate.  Data describing tangential elastic modulus 
versus stress relations were fit with semi-logarithmic regression equations, each of which provided a significant F-
statistic for the regression and an adjusted r2>0.90.  Differences between regression coefficients were evaluated 
using ANOVA with post-hoc tests, as appropriate.   In all cases, p<0.05 was taken to reflect statistical significance. 
RESULTS 
 At the time of use, body mass was not different between the three strains of mice at either the 12-13 week or 
22-23 week ages.  At 12-13 weeks, C57 averaged 22±2 g, while ApoE and LDLR averaged 21±2 and 22±2 g, 
respectively.  At 22-23 weeks, C57 averaged 31±2 g, as compared to 30±3 g for ApoE and 31±2 g for LDLR.  
While no differences were observed for mean arterial pressure across the three strains at 12-13 weeks (84±6 mmHg 
for C57; 86±5 mmHg for ApoE and 90±5 mmHg for LDLR), LDLR mice exhibited a significant increase in blood 
pressure by 22-23 weeks, reaching 112±6 mmHg, as compared to 84±5 mmHg in C57 and 92±5 mmHg in ApoE. 
 Figure 1 presents the severity of hypercholesterolemia (Panel A) and hypertriglyceridemia (Panel B) across 
the three mouse strains in the present study.  While both ApoE and LDLR were significantly hypercholesterolemic 
as compared to C57 at both 12-13 and 22-23 weeks of age, total cholesterol was also significantly elevated in LDLR 
as compared to ApoE at both ages (Panel A).  In contrast, plasma triglyceride levels were only elevated in ApoE 
mice, and this effect was present at both age ranges (Panel B).  Between age groups, within a strain, there were no 
differences in plasma cholesterol or triglycerides. 
 Figure 2 summarizes data describing basic deformational alterations to skeletal muscle arteries of C57, 
ApoE and LDLR mice at 12-13 and 22-23 weeks of age in response to increasing intralumenal pressure.  The 
increase in arterial inner (Panel A) and outer diameter (Panel B) in response to increasing intralumenal pressure was 
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blunted in ApoE and LDLR as compared to responses in C57.  This blunting was greater with regard to inner 
diameter in LDLR mice, and as such there was a tendency for wall thickness to be elevated in LDLR with 
increasing age (Panel C).   Total cross-sectional wall area demonstrated some decline with age within a strain, but 
with the exception of comparisons to the younger C57 mice, this did not exhibit a consistent pattern (Panel D).  The 
tendency for an increased wall thickness with increasing hypercholesterolemia was also evident in terms of 
wall:lumen ratio (Panel E), as the older group of LDLR exhibited a significantly greater ratio over the range of 
intralumenal pressure.  Finally, arterial wall incremental distensibility was reduced in LDLR with age as compared 
to either ApoE or C57 mice throughout the early range of intralumenal pressures (Panel F).  However, beyond these 
points, all of the curves became superimposable. 
 Figure 3 presents data describing the changes in arterial circumferential wall stress versus strain (Panel A) 
and the tangential elastic modulus versus stress (Panel B) relations across the three strains.  With increasing age and 
dyslipidemia, there was a progressive left-shifting of the stress versus strain relation that was most pronounced in 
LDLR as compared to ApoE (where no statistically significant shift in the curve was determined).  This was also 
apparent in the ET versus stress relation, where a modest trend toward an increasing slope in arteries from ApoE 
versus C57 was present, but that a striking shift in this relation in arteries from LDLR was evident compared to 
either other group. 
 The changes in microvessel density with age in control and dyslipidemic mice are summarized in Figure 4.  
While microvessel density was stable in skeletal muscle of C57 mice between 12-13 and 22-23 weeks of age, a 
consistent and increasing rarefaction in muscle of ApoE mice was exhibited, such that it was reduced at 12-13 
weeks and a further rarefaction continued to 22-23 weeks of age.  In contrast, there was no evidence for a significant 
rarefaction of the skeletal muscle microcirculation of LDLR at 12-13 weeks of age.  However, the data presented in 
Figure 4 suggest that microvascular rarefaction was delayed in LDLR as compared to ApoE, as a significant 
reduction in microvessel density was evident by 22-23 weeks of age. 
 Data describing the plasma levels of specific biomarkers or contributors to vascular dysfunction are 
summarized in Figure 5.  Plasma nitrotyrosine, an indicator of chronic vascular oxidant stress, was significantly 
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elevated in both ApoE and LDLR as compared to C57, and this was evident at both age ranges (Panel A).  
However, no differences were determined between ApoE and LDLR in terms of nitrotyrosine.  Plasma 
concentrations of tumor necrosis factors-α (TNF-α) were elevated in both ApoE and LDLR as compared to C57 at 
both age ranges, although the magnitude of this increase was greater in ApoE mice (Panel B).  In both ApoE and 
LDLR, plasma interleukin-1β (IL-1β) was elevated as compared to levels determined in C57 at both 12-13 and 22-
23 weeks of age, although no differences were determined between the two dyslipidemic strains (Panel C).  Panel D 
presents plasma levels of monocyte chemoattractant protein-1 (MCP-1) between the three strains.  While ApoE 
mice consistently demonstrated a significant increase in MCP-1 versus C57, this effect was much more pronounced 
in LDLR, where MCP-1 levels were also increased over that in ApoE. 
 Using conduit arteries, indices of vascular endothelial function are summarized in Figure 6.  Following 
challenge with arachidonic acid, pooled arteries from all strains demonstrated a comparable, maintained ability to 
produce PGI2, as estimated from its breakdown product, 6-keto-PGF1α (Panel A).  In contrast, arachidonic acid-
induced production of TxA2, estimated from its breakdown product 11-dehydro-TxB2, was significantly increased at 
both 12-13 and 22-23 weeks of age in arteries from ApoE as compared to C57 mice (Panel B).  A similar pattern 
was also evident for thromboxane production in arteries from LDLR mice, although this lagged behind that in 
ApoE.   Finally, vascular bioavailability of nitric oxide, estimated from its production following challenge with 
methacholine was dramatically attenuated in arteries from both ApoE and LDLR versus control at both 12-13 and 
22-23 weeks (Panel C).  Treatment of arteries with L-NAME abolished methacholine-induced nitric oxide 
production in all cases (data not shown). 
DISCUSSION 
 While previous studies involving dyslipidemic humans and animal have demonstrated that elevated plasma 
cholesterol and triglycerides represent a significant risk factor for the development of atherosclerotic vascular 
disease (10, 13, 15, 23, 31), less thoroughly evaluated are alterations to vascular mechanics and almost completely 
unknown are the distal impact of these conditions on muscle vascularity.  The results of the present study revealed 
several key observations.  First, while both FH and FCH in mice resulted in an extensive remodeling of the skeletal 
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muscle microcirculation, the specifics of the remodeling varied between strains. In FH, this remodeling was 
predominantly at the level of the resistance arterial wall through in increased wall stiffness, while in FCH, the 
remodeling was localized more at the level of the microvascular networks through an increased rarefaction.  Further, 
the results from the present study identify potential contributors for future interrogation under each condition. 
Specifically, in FH, predictors such as cholesterol severity and the expression of inflammatory markers for cell 
attraction/adhesion are implicated for the developing stiffness of the resistance arterial wall. Alternatively, in FCH, 
the severity of hypertriglyceridemia, the presence of pro-apoptotic markers of inflammation, and alterations to 
endothelial metabolism of arachidonic acid were identified as correlates of the microvascular network remodeling.   
 The initial observation from the present study was that, while both familial hypercholesterolemia and 
familial combined hyperlipidemia can impact vascular wall mechanics, the alterations to wall mechanics with FH 
(in LDLR mice) develop more rapidly and are more severe than those determined under conditions of FCH (in 
ApoE mice).   While the blunted distention of the arterial wall with increased pressure was in keeping with the 
observations of a decreased deformability of the vessel wall with chronic dyslipidemia in both strains, this was 
considerably pronounced in LDLR.  When combined with the trend toward an increased wall thickness determined 
in arteries from LDLR mice, this resulted in significant elevations in wall:lumen ratio, an observation that has also 
been demonstrated in human subjects with chronic hypercholesterolemia (12, 21) and in the ApoE/LDLR double 
knockout mouse (6).  Taken together, these factors also resulted in the reduction in arterial wall incremental 
distensibility that was determined for both dyslipidemic strains, although more pronounced in LDLR than in ApoE.   
 These data describing the mechanical characteristics of the resistance arterial wall become more informative 
when placed in the context of circumferential stress versus strain relations (Figure 3A) and the relationship between 
tangential elastic modulus (ET) versus circumferential stress (Figure 3B).  The left-shifting of the stress versus strain 
relation, as indicated by the increased magnitude of the β coefficient from the exponential equation fit to the data, 
demonstrates that the stiffness of the resistance artery is increased with FH in LDLR mice.  While this process also 
develops in ApoE, it is considerably less robust and slower to develop.  The shape of the ET versus stress curves 
reveals an interesting insight into the behavior of the vascular wall.  Had these data been best approximated by a 
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linear model, this would have suggested that the increased stiffness of the arterial wall in LDLR as compared to C57 
developed via contributions throughout the range of the intralumenal pressure range.  However, these data were 
better approximated by a non-linear equation (with a superior adjusted r-squared), with the majority of the 
differences between responses in LDLR and C57 being accounted for over the range of relatively low stresses.  
From the perspective of functional restraints on perfusion, this suggests that the remodeling that develops in the 
arterial wall of LDLR may be primarily relevant in terms of restricting diameter at lower intralumenal pressures.  
Future investigation into the physical alterations to the architecture of the vessel wall, and how this contributes to 
the shift in these mechanical responses, especially in LDLR mice appears to be well justified. 
 The other major observation from the present study was that the remodeling of skeletal muscle 
microvascular networks (microvessel rarefaction) was most pronounced under conditions of familial combined 
hyperlipidemia.  Notably, while the reduction in microvessel density with familial hypercholesterolemia in LDLR 
mice was present by 22-23 weeks of age, the rarefaction that developed in skeletal muscle of ApoE mice was much 
more robust, and was clearly identifiable by 12-13 weeks with increasing severity in the older age range.  This 
observation, when taken in context with the impacts of the two models of genetic dyslipidemia on vascular wall 
mechanics, has a potentially significant implication.  Specifically, familial hypercholesterolemia and familial 
combined hyperlipidemia, while ultimately leading to directionally consistent outcomes in terms of vascular 
remodeling, preferentially impact different sites along the vascular tree.  Familial hypercholesterolemia is associated 
with an outcome that more rapidly and severely impacts vascular wall distensibility with effects on microvessel 
density that are delayed and more muted.  Conversely, the vascular remodeling associated with familial combined 
hyperlipidemia is more targeted to microvessel rarefaction, with vascular wall remodeling being less pronounced.   
 At the outset, the obvious issue to be addressed is how familial hypercholesterolemia and familial combined 
hyperlipidemia differ with respect to systemic markers of cardiovascular disease risk and vascular function.  While 
both ApoE and LDLR exhibit a significant hypercholesterolemia (Figure 1), this is considerably greater in LDLR 
than in ApoE.  Further, ApoE mice also demonstrate a significant hypertriglyceridemia that is not present in LDLR.  
The data presented in Figure 5 may provide additional insight in how systemic markers of inflammation may help to 
46
Dyslipidemia and vascular remodeling 
 
discriminate between the impact of FH and FCH.   Plasma levels of TNF-α were much higher in ApoE mice at both 
ages as compared to LDLR, while levels of MCP-1 exhibited a reversed relationship.  However, neither the 
systemic marker of chronic oxidant stress (nitrotyrosine), nor the inflammatory marker IL-1β, while elevated in 
ApoE and LDLR versus C57, were able to provide for discrimination between the two dyslipidemic strains. 
 Previous studies have suggested that alterations to endothelial function can play a critical role in both 
vascular wall (17, 38) and vascular network (26) remodeling.  As such, we utilized three indices of endothelial 
function in arteries as potential discriminating factors between FH and FCH in terms of vascular remodeling; 
methacholine-induced nitric oxide bioavailability, and arachidonic acid-induced PGI2 or TxA2 production (Figure 
6).  Vascular nitric oxide bioavailability represented a poor discriminator between ApoE and LDLR mice, as 
methacholine-induced NO production was rapidly and severely attenuated in both strains.  Similarly, the generation 
of PGI2 (through the measurement of 6-keto-PGF1α) was also a poor discriminator between the dyslipidemic mice, 
as this parameter was largely intact in both strains at both age ranges.  The vascular production of TxA2, as 
estimated from the arachidonic acid-induced generation of 11-dehydro-TxB2 was a stronger discriminator, showing 
a rapid and significant elevation in ApoE mice as compared to C57, which was maintained to 22-23 weeks.  In 
contrast, 11-dehydro-TxB2 production in arteries of LDLR was less robust and lagged behind that in arteries in 
ApoE. 
 Taken together, these results may begin to provide for a framework distinguishing vascular structural 
outcomes between familial hypercholesterolemia in LDLR mice and familial combined hyperlipidemia in ApoE 
mice.  In LDLR mice, the development of FH is associated with a more rapid and robust remodeling of the arterial 
wall, leading to an increased stiffness at lower intralumenal pressures which continues to impact vessel dimension at 
higher levels of distending pressure.  In contrast, microvascular rarefaction develops more slowly under these 
systemic conditions, reaching significance by 22-23 weeks.  Based on the results of the present study, this vascular 
structural outcome may be well predicted by severity of the hypercholesterolemia and increased MCP-1 expression.  
This potential linkage has been tentatively identified previously, as in mouse (28, 42) and rabbit (30) models of 
hypercholesterolemia and in humans afflicted with FH (5, 29), a particularly strong correlation between MCP-1, 
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cholesterol and atherogenesis has been identified.  One of the most compelling possibilities for the role of MCP-1 
in contributing to vascular wall remodeling in dyslipidemia was indentified in a recent study by Jagavelu et al. 
(22).  In this study, the authors investigated the importance of MAP kinase-activated protein kinase-2 (MK2) in 
contributing to endothelial dysfunction and atherogenesis.  As a key regulator of inflammatory processes, the 
systemic level of activation of MK2 was correlated with the level of endothelial dysfunction and 
lipid/macrophage in the vessel wall in LDLR mice, an observation that was independent from the level of pro-
atherogenic lipoproteins.  With direct relevance to the present study, systemic gene deletion of MK2 in LDLR 
mice or siRNA silencing of MK2 in endothelial cells was associated with a decreased aortic expression of 
VCAM-1 and MCP-1, key mediators of macrophage recruitment into the vessel wall.  However, to our 
knowledge, this previous work has not been extended significantly at present and does not include vascular wall 
mechanics. 
 In the ApoE mouse, the development of FCH is associated with a microvascular rarefaction that develops 
quickly, while arterial wall remodeling is delayed.  This outcome appears to be well predicted by a severe 
hypertriglyceridemia in the face of significant hypercholesterolemia, and is well tracked by an increase in the 
plasma level of TNF-α and the vascular production of TxA2.  While existing studies have linked plasma levels of 
TNF-α (33) and altered arachidonic acid metabolism (4) with microvascular rarefaction in other models of CVD 
risk factors, this possibility represents a novel concept in mouse models of genetic dyslipidemia and will require 
further verification and, assuming validation, investment of resources to determine underlying mechanistic 
contributors and ameliorative interventions. 
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Table 1.  Initial values for the dimensions of isolated skeletal muscle resistance arteries from C57, ApoE and LDLR 
mice at the lowest intralumenal pressure (5 mmHg). * p<0.05 vs. 12-13W in that strain ; † p<0.05 vs. C57 at that 
age; ‡ p<0.05 vs. ApoE at that age. 
 
 
C57 
12-13W          22-23W 
ApoE 
12-13W          22-23W 
LDLR 
12-13W         22-23W 
Inner Diameter (μm) 45.0±4.5 54.5±5.1 52.7±4.9 58.8±4.5 56.0±4.6 63.8±4.9 
Outer Diameter (μm) 93.3±5.0 104.1±4.9 100.7±5.5 108.7±4.9 105.1±4.3 101.5±5.3 
Wall Thickness (μm) 48.3±4.0 49.5±3.9 48.0±4.1 49.8±3.9 49.0±4.0 38.0±4.0†‡ 
CSWA (μm2) 5250±306 6173±321* 5785±319 6559±266* 6200±228† 4914±285*†‡ 
Wall:Lumen 1.08±0.10 0.96±0.09 0.96±0.11 0.88±0.09 0.89±0.09 0.60±0.10*†‡ 
 
56
Dyslipidemia and vascular remodeling 
 
FIGURE LEGENDS 
Figure 1.  Plasma total cholesterol (Panel A) and triglycerides (Panel B) in C57, ApoE and LDLR mice at 12-13 
weeks or 22-23 weeks of age.  Data are presented as mean±SEM, n=8 animals for each group.  * p<0.05 vs. C57 at 
that age; † p<0.05 vs. ApoE at that age.  
 
Figure 2.  Passive mechanical characteristics of the skeletal muscle resistance arterial wall in C57, ApoE and LDLR 
mice at 12-13 weeks or 22-23 weeks of age.  Data (mean±SEM) are presented for arterial inner diameter (Panel A), 
arterial outer diameter (Panel B), arterial wall thickness (Panel C), arterial cross sectional wall area (Panel D), 
wall:lumen ratio (Panel E) and incremental distensibility (Panel D) over a range of increasing intralumenal pressure, 
n=8 animals for each group.   * p<0.05 vs. that strain at 12-13 weeks; † p<0.05 vs. C57 at that age; ‡ p<0.05 vs. 
ApoE at that age. 
 
Figure 3.  Circumferential wall stress versus strain (Panel A) and tangential elastic modulus versus wall stress 
(Panel B) relationships in passive skeletal muscle resistance arteries from C57, ApoE and LDLR mice at 12-13 
weeks or 22-23 weeks of age.  Data are presented as mean±SEM, n=8 animals for each group.  * p<0.05 vs. that 
strain at 12-13 weeks; † p<0.05 vs. C57 at that age; ‡ p<0.05 vs. ApoE at that age. 
 
Figure 4.  Gastrocnemius muscle microvessel density in C57, ApoE and LDLR mice at 12-13 weeks or 22-23 
weeks of age.  Data are presented as mean±SEM, n=8 animals for each group.  * p<0.05 vs. C57 at that age; † 
p<0.05 vs. ApoE at that age.  
 
Figure 5.  Plasma nitrotyrosine (Panel A), TNF-α (Panel B), IL-1β (Panel C) and MCP-1 (Panel D) in C57, ApoE 
and LDLR mice at 12-13 weeks or 22-23 weeks of age.  Data are presented as mean±SEM, n=8 animals for each 
group.  * p<0.05 vs. C57 at that age; † p<0.05 vs. ApoE at that age.  
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Figure 6.  Data describing the production of nitric oxide (from aortae, Panel A), 6-keto-PGF1α (from pooled 
arteries, Panel B) or 11-dehydro-TxB2 (from pooled arteries, Panel C) of C57, ApoE and LDLR.  Data, presented as 
mean±SEM, are shown in response to application of 10-4 M methacholine (Panel A) or 10-6 M arachidonic acid 
(Panels B and C).  n=6 animals for each group, with each n representing either an aorta or pooled arteries from an 
individual mouse; please see text for details.  * p<0.05 vs. C57 at that age; † p<0.05 vs. ApoE at that age. 
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ABSTRACT 
With most cardiovascular disease risk factors, endothelium-dependent dilation of skeletal muscle resistance 
arterioles is compromised, although with hypercholesterolemia, impairments to reactivity are not consistently 
observed.  Using apolipoprotein E (ApoE) and low density lipoprotein receptor (LDLR) gene deletion male mouse 
models of hypercholesterolemia at 20 weeks of age, the hypothesis tested in this study was that arteriolar dilation 
would be maintained due to an increased stimulus-induced production of dilator metabolites via cyclooxygenase 
and cytochrome P450 epoxygenase pathways.   Arterioles from both strains demonstrated mild reductions in 
dilation to hypoxia and acetylcholine versus responses in C57/Bl/6J (C57) controls.  However, while inhibition 
of nitric oxide synthase (NOS) attenuated dilation in arterioles from C57, this effect was absent in ApoE or 
LDLR.  In contrast, cyclooxygenase-dependent portions of dilator reactivity were maintained across the three 
strains.  Notably, while combined NOS and cyclooxygenase inhibition abolished arteriolar responses to hypoxia 
and acetylcholine in C57, significant reactivity remained in ApoE and LDLR.  While inhibition of cytochrome 
P450 ω-hydroxylase and epoxygenases had no effect on this residual reactivity in ApoE and LDLR, inhibition 
of 12/15 lipoxygenase with nordihydroguaiaretic acid abolished the residual reactivity.  With both hypoxic and 
methacholine challenges, arteries from ApoE and LDLR demonstrated an increased production of both 12(S)- 
and 15(S)-HETE, end products of arachidonic acid metabolism via 12/15 lipoxygenase, a response that was not 
present in C57.  These results suggest that with development of hypercholesterolemia, mechanisms contributing 
to dilator reactivity in skeletal muscle arterioles are modified such that net reactivity to endothelium-dependent 
stimuli is largely intact. 
 
Key Words: skeletal muscle microcirculation, endothelium-dependent dilation, vascular reactivity, mouse 
models of cardiovascular disease 
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INTRODUCTION 
 It has been well established that development of the hypercholesterolemic condition is a profound risk factor 
for the evolution of coronary and peripheral arterial disease (1).  From an epidemiological perspective, recent 
studies from the Centers for Disease Control have indicated that under conditions of dyslipidemia, a 10% reduction 
in total cholesterol levels can result in an estimated 30% reduction in the incidence of coronary artery disease (1).  
However, while hypercholesterolemia is a clear and profound risk factor for the initiation and progression of 
peripheral arterial disease, most notably through an increased likelihood for the risk of developing atherosclerotic 
depositions (16, 44), an understanding of the impact of hypercholesterolemia on the patterns of vascular reactivity 
has thus far demonstrated considerably less consensus. 
 In previous studies of human subjects afflicted with genetic dyslipidemia, particularly familial 
hypercholesterolemia (a genetic disorder resulting in exceptionally high low density lipoprotein [LDL] level, in the 
face of an otherwise relatively normal lipid profile), arterial dilator reactivity during recovery from brief occlusion 
(i.e., flow-mediated dilation or reactive hyperemia) was found to be significantly attenuated as compared to 
responses in normocholesterolemic subjects (2, 6, 8, 20, 29, 39).  Further,  given the strong dependence of the flow-
mediated response on endothelial nitric oxide bioavailability (22), many of these previous results have implicated 
oxidant radical scavenging of nitric oxide (NO), thus reducing its bioavailability, as an underlying mechanism 
contributing to impaired reactivity (6, 8, 29, 42).   However, results from other studies suggest that, while dilator 
responses to NO-dependent stimuli are impaired with profound hypercholesterolemia, vasodilation in response to 
metabolic stimuli are largely intact (7) and may suggest that compensatory mechanisms could be emerging in order 
to ameliorate the effects of any loss in reactivity owing to an impaired NO bioavailability.  Notably, Paniagua et al. 
(34) demonstrated that shear stress-induced dilation of adipose tissue microvessels from hypercholesterolemic 
subjects was preserved despite a diminished activity of endothelial nitric oxide synthase.  The maintenance of 
vascular reactivity under conditions of hypercholesterolemia has also been suggested by work from Laughlin’s 
group, as these investigators have demonstrated that a high fat, high cholesterol diet had only mild-moderate effects 
on coronary arteriolar (17) or femoral artery (47) dilation mediated through the vascular endothelium. 
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 Previous studies have suggested that dilator responses of thoracic aortic rings (4, 5) and coronary arteries 
(25) from hyperlipidemic apolipoprotein E gene deletion mice ingesting a normal diet.  However, dilator responses 
in these mice were profoundly impaired following chronic ingestion of high fat/high cholesterol diets.  Given the 
recent study by Wolfle and de Wit (46), wherein the endothelium-dependent dilator and conducted responses 
following challenge with acetylcholine were intact in the apolipoprotein E and low density lipoprotein receptor gene 
deletion mouse models of hypercholesterolemia, and the previous work of  Pfister et al. (36) which suggests that the 
pathways of arachidonic acid-induced arterial dilation can be radically altered in hypercholesterolemic rabbits, the 
purpose of the present study was to determine the effects of profound hypercholesterolemia of genetic origin on 
mechanisms of endothelium-dependent dilator responses of skeletal muscle resistance arterioles.  Using both the 
apolipoprotein E and low density lipoprotein receptor gene deletion mouse models of hypercholesterolemia, the 
hypothesis tested in this study was that endothelium-dependent dilator reactivity of skeletal muscle arterioles in 
these animals would be maintained, despite profound hypercholesterolemia and that this would be manifested 
through an increased stimulus-induced production of dilator metabolites via cyclooxygenase and cytochrome P450 
epoxygenase pathways.   
MATERIALS AND METHODS 
Animals:  The present study used three strains of mice, the C57/Bl/6J (C57) as the control strain and the 
apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) and low density lipoprotein receptor gene deletion 
(B6.129S7-Ldlrtm1Her/J; LDLR) mice on the C57/Bl/6J background.  All mice were purchased from Jackson 
Laboratories (Bar Harbor, ME) at 6 weeks of age.  The ApoE gene deletion mouse model of 
hypercholesterolemia manifests a type III hyperlipidemia in which both plasma cholesterol and triglyceride 
levels are elevated, although the elevations in LDL are not as severe as in the LDLR gene deletion mouse (37). 
In contrast, the LDLR gene deletion mouse is a model of human familial hypercholesterolemia, manifesting a 
profound increase in serum LDL levels while ingesting a normal diet (19). 
 Male mice of each strain were fed standard chow and drinking water ad libitum and were housed in an 
AAALAC-accredited animal care facility at the West Virginia University Health Sciences Center and all protocols 
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received prior IACUC approval.  At 20 weeks of age, after an overnight fast, mice were anesthetized with injections 
of sodium pentobarbital (50 mg•kg-1 i.p.), and received tracheal intubation to facilitate maintenance of a patent 
airway.  In all mice, a carotid artery was cannulated for determination of arterial pressure.  Blood aliquots were 
drawn from the jugular vein cannula for determination of glucose and insulin (Linco) and a lipid profile levels 
(Waco).  The 20 week age was used in order to allow us to investigate alterations to microvascular 
structure/function in the presence of chronic dyslipidemia.  Further, at this age, the degree of the dysfunction was 
not so severe that it would not be amenable to amelioration via interventional strategies.  Thus, the use of this age 
range allows us to examine both mechanisms underlying dysfunction as well as the efficacy of interventional 
strategies for improving microvascular outcomes. 
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the intramuscular 
continuation of the right gracilis artery was surgically removed and cannulated, as described previously for rats 
(14).  These first order arterioles were extended to their approximate in situ length and were equilibrated at 80% 
of the animal's mean arterial pressure in order to approximate the in vivo intralumenal pressure experienced by 
the animal (26).  Following equilibration, arteriolar reactivity was evaluated in response to: 1) hypoxia; a 
reduction in superfusate and perfusate PO2 from ~135 mmHg (21% O2) to ~40 mmHg (0% O2), 2) acetylcholine 
(10-10 M – 10-6 M; Sigma), 3) sodium nitroprusside (10-10 M – 10-6 M; Sigma) and 4) prostacyclin (10-10 M – 10-6 
M; Biomol).  Following assessments of arteriolar reactivity, the perfusate and superfusate were replaced with 
Ca2+-free PSS and vessels were treated with 10-7 M phenylephrine until all reactivity and tone were abolished.  
Subsequently, arteriolar intralumenal pressure was altered, in 20 mmHg increments, between 0 mmHg and 140 
mmHg and the inner and outer diameter of arterioles was determined at each pressure.  These data were used to 
calculate arteriolar wall mechanics which were used as indicators of structural alterations to individual 
microvessels (13). 
 Removal of the vessel endothelium was accomplished by passing several air bubbles through the 
perfusate line into the isolated arteriole, the efficacy of which was determined from a loss of all dilator 
reactivity in response to application of 10-6 M acetylcholine (14).  To assess the contribution of NO production 
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or the generation of metabolites via cyclooxygenase as mediators of arteriolar dilator reactivity, isolated vessels 
were treated with the NO synthase inhibitor L-NG-nitroarginine methyl ester (L-NAME; 10-4 M; Sigma) or the 
cyclooxygenase antagonist indomethacin (INDO; 10-6 M; Sigma), respectively.  Additionally, to determine the 
contribution of metabolites of arachidonic acid mediated via cytochrome P450 enzymes, vessels were treated 
with the suicide substrate inhibitor 17-octadecynoic acid (17-ODYA; 10-5 M; Sigma).  Previous studies have 
demonstrated that 17-ODYA profoundly attenuates both the ω-hydroxylation (producing 20-
hydroxyeicosatetraenoic acid; 20-HETE) and epoxygenation (producing epoxyeicosatrienoic acids; EETs) 
reactions of arachidonic acid through cytochrome P450 (45), thus preventing changes to vascular levels of 20-
HETE or EETs as contributing mediators to endothelium-dependent dilation (10, 14, 15, 33).   To assess the 
contribution of lipoxygenase metabolites to the patterns of arteriolar dilation, vessels were treated with 
nordihydroguaiaretic acid (NDGA; 3×10-5 M; Biomol), a selective inhibitor of 12- and 15-lipoxygenases (11, 
38, 48). 
Measurement of Vascular Nitric Oxide Bioavailability: From each animal, the aorta was removed and vascular 
NO production was assessed using amperometric sensors (World Precision Instruments).  Briefly, aortae were 
isolated, sectioned longitudinally, pinned in a silastic coated dish and superfused with warmed (37°C) PSS 
equilibrated with 95% O2/5% CO2.  The NO sensor (ISO-NOPF 100) was placed in close apposition to the 
endothelial surface and a baseline level of current was obtained.  Subsequently, aortae were exposed to either 
acute reductions in PO2 from ~135 mmHg to ~40 mmHg (as described above) or increasing concentrations of 
methacholine (10-10 M –10-6 M) and changes in current were determined.  To verify that recorded data 
represented endothelium-dependent NO release, responses were re-evaluated following acute treatment of 
aortae with L-NAME (10-4 M).     
Determination of Vascular Metabolites of Arachidonic Acid:  Vascular production of 6-keto-prostaglandin F1α  (6-
keto-PGF1α; the breakdown product of PGI2; ref. 31), 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE; the stable 
product from the reduction of 12(S)-hydroperoxytetraenoiceicosatetrenoic acid [12(S)-HpETE], the 12-lipoxyenase 
metabolite of arachidonic acid; refs. 3, 40, 49) and 15-hydroxyeicosatetrenoic acid (15(S)-HETE; the major 
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hydroxyl derivative of arachidonic acid when metabolized by 15-lipoxygenase; refs. 3, 27, 43, 48, 49) in response to 
hypoxia or methacholine within the three mouse groups was assessed using pooled conduit arteries (e.g., femoral, 
saphenous, iliac, carotid arteries) from each mouse.  Vessels were incubated in microcentrifuge tubes in 1 ml of 
physiological salt solution for 30 minutes under control conditions (21% O2), after which time either the 
equilibration gas was switched to 0% O2 or methacholine (10-6 M) was added to the tube for an additional 30 
minutes.  After the second 30 minute period, the PSS was removed from the tube, frozen in liquid N2 and stored at -
80°C.  Metabolite release by the vessels was determined using commercially available EIA kits for 6-keto-PGF1α 
(Cayman), 12(S)-HETE (Assay Designs) and 15(S)-HETE (Assay Designs). 
Data and Statistical Analyses:  Active tone of individual arterioles at the equilibration pressure was calculated 
as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to Ca2+-free PSS, and Dmax is the 
maximum diameter measured at the equilibration pressure in Ca2+-free PSS.   
 Dilator responses of isolated arterioles following challenge with dilator agonists were fit with the three-
parameter logistic equation: 
⎥⎦
⎤⎢⎣
⎡
+
−+= −xEDy 50log101
minmaxmin  
where y  represents the change in arteriolar diameter, “min” and “max” represent the lower and upper bounds, 
respectively, of the change in arteriolar diameter with increasing agonist concentration, x  is the logarithm of the 
agonist concentration and 50log ED  represents the logarithm of the agonist concentration ( x ) at which the response 
( y ) is halfway between the lower and upper bounds.     
The passive arteriolar incremental distensibility (% change in arteriolar diameter/mmHg) was calculated 
as: 
( ) 100×⎟⎠⎞⎜⎝⎛ Δ×Δ= ILINC PIDIDDIST  
where IDΔ  represents the change in internal arteriolar diameter for each incremental change in intralumenal 
pressure ( ILPΔ ).   
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 Data describing the vascular production of NO in response to methacholine challenge were fit with a linear 
regression equation ( )(10 xy βα += ), where ( y ) represents the nitric oxide production, ( x ) represents the 
concentration of methacholine, ( 0α ) represents an intercept term, and ( 1β ) represents the rate of change in nitric 
oxide production for a change in methacholine concentration (slope). 
 Data are presented as mean±SEM.  Statistically significant differences in measured and calculated 
parameters in the present study were determined using analysis of variance (ANOVA).  In all cases, Student-
Newman-Keuls post hoc test was used when appropriate and p<0.05 was taken to reflect statistical significance.   
RESULTS 
 Table 1 presents baseline characteristics of the three mouse groups used in the present study.  While all mice 
were of comparable mass at 20 weeks of age, LDLR mice demonstrated a statistically significant elevation in mean 
arterial pressure and insulin resistance as compared to values in either C57 or ApoE.  While both ApoE and LDLR 
manifested a profound hypercholesterolemia, most severe in LDLR animals, these animals also exhibited 
hypertriglyceridemia as well, which was most substantial in ApoE mice.   Additionally, isolated arterioles from 
ApoE and LDLR mice, while exhibiting comparable diameters with C57 under active conditions, demonstrated a 
progressive reduction in inner diameter under passive (calcium-free) conditions. 
 Figure 1 presents dilator reactivity for isolated arterioles from C57, ApoE and LDLR mice in response to 
challenge with hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B), sodium nitroprusside 
(Panel C) and prostacyclin (Panel D).  In response to hypoxia or acetylcholine, where arteriolar dilation is strongly 
endothelium-dependent, responses in vessels from ApoE and LDLR mice were only modestly attenuated as 
compared to responses determined in C57 control animals.  In Panels C (sodium nitroprusside) and D (prostacyclin), 
where dilator responses to these stimuli are endothelium-independent, arteriolar reactivity was also predominantly 
intact, demonstrating only mild attenuation. 
 Data describing the passive mechanical characteristics of the skeletal muscle resistance arteriolar wall in the 
mouse groups for the present study are summarized in Figure 2.  Under Ca2+-free conditions, the increase in vessel 
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diameter with elevated intralumenal pressure was consistently reduced in isolated arterioles of LDLR as compared 
to C57, with the majority of this impact being observed at higher levels of pressure (Panel A).  While a directionally 
consistent effect was also determined in a comparison of ApoE to C57, this effect was not as pronounced.  
However, calculated incremental distensibility, although demonstrating a consistent trend towards a reduced 
deformability of the vessel wall in the hypercholesterolemic animals, was not significantly different between the 
three mouse groups (Panel B). 
 Figure 3 presents vascular reactivity to hypoxia (Panel A) and to increasing concentrations of acetylcholine 
(Panels B-D) in isolated arterioles of C57, ApoE and LDLR mice following inhibition of nitric oxide synthase, 
cyclooxygenase and both pathways.  In response to hypoxia, C57 mice demonstrated an arteriolar reactivity that 
was dependent on the release of both NO and PGI2 from the vascular endothelium.  Alternatively, in both ApoE and 
LDLR mice, arteriolar reactivity to hypoxia demonstrated no statistically significant contribution from nitric oxide 
synthase, although a significant contribution for metabolites of arachidonic acid via cyclooxygenase remained intact 
(Panel A).  Interestingly, combined inhibition of NOS and cyclooxygenase in both hypercholesterolemic mouse 
strains did not abolish arteriolar dilation to hypoxia, as a significant reactivity to reduced PO2 remained intact.  
Vascular responses to challenge with acetylcholine demonstrated a comparable pattern to that for hypoxia.  In 
arterioles from C57 mice (Panel B), dilation to acetylcholine was an integrated response mediated through 
contribution of NO and PGI2.  In ApoE (Panel C) and LDLR (Panel D), the NO-dependent portion of arteriolar 
dilation in response to acetylcholine was attenuated, and the cyclooxygenase-dependent portion remained intact.  
Further, a significant acetylcholine-induced arteriolar dilation remained in ApoE and LDLR mice despite combined 
treatment with both L-NAME and indomethacin.  
 Figure 4 presents data describing vascular NO and PGI2 production from C57, ApoE and LDLR mice in 
response to hypoxic and methacholine challenge.  Hypoxia-induced NO production was pronounced in aortae from 
C57 and demonstrated a progressive attenuation in ApoE and LDLR mice, such that this response was entirely 
abolished in the latter strain (Panel A).  A similar pattern was present in response to methacholine challenge, as the 
agonist-induced generation of NO in C57 was abrogated in both ApoE and LDLR mice (Panel B).  In contrast, 
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production of prostacyclin (from 6-keto-PGF1α levels) from pooled arteries was comparable between C57, ApoE 
and LDLR in response to either reduced PO2 (Panel C) or increasing concentrations of methacholine (Panel D). 
 The role of metabolites of arachidonic acid from cytochrome P450 enzymes in contributing of hypoxia- or 
acetylcholine-induced vasodilation in C57, ApoE and LDLR mice are summarized in Figure 5.  Hypoxic dilation of 
isolated arterioles from these mice was unaffected by application of 17-ODYA (Panel A), and combined application 
of 17-ODYA with both L-NAME and indomethacin resulted in a reduction in dilator reactivity that was extremely 
similar to that determined for NOS and cyclooxygense inhibition alone (as shown in Figure 3, Panel A).  This 
pattern was repeated with acetylcholine challenge in arterioles of C57 (Panel B), ApoE (Panel C) and LDLR (Panel 
D), as treatment with 17-ODYA alone had minimal impact on acetylcholine-induced dilation and combined 
treatment with 17-ODYA, L-NAME and indomethacin had an effect that was nearly identical to combined 
administration of L-NAME and indomethacin in the absence of 17-ODYA. 
 The effects of 12/15 lipoxygenase inhibition with NDGA on hypoxia- and acetylcholine-induced arteriolar 
dilation in the mouse groups of the present study are presented in Figure 6.  With acute reductions in PO2 (Panel A), 
treatment with NDGA alone had no substantial impact on responses in C57 mice, but significantly reduced hypoxic 
dilation in arterioles of ApoE and LDLR mice.  Combined treatment of arterioles with L-NAME, indomethacin and 
NDGA abolished the responses of vessels from all groups in response to hypoxia.    Comparable results were also 
determined in response to acetylcholine challenge, as NDGA treatment had minimal impact on arteriolar dilation in 
response to acetylcholine in C57 mice (Panel A), but significantly reduced these responses in ApoE (Panel C) and 
LDLR (Panel D).  Combined treatment with L-NAME, indomethacin, and NDGA abolished all arteriolar 
acetylcholine-induced reactivity in the hypercholesterolemic mice. 
 Figure 7 presents data describing the vascular production of 12(S)-HETE and 15(S)-HETE from the mouse 
groups in the present study in response to hypoxia and challenge with methacholine.  The production of 12(S)-
HETE from pooled arteries following exposure to hypoxia (Panel A) or methacholine (Panel B) was minimal in C57 
mice, but was significantly increased in both ApoE and LDLR mice.  Similarly, arterial production of 15(S)-HETE 
was also significantly increased over that in C57 mice in ApoE and LDLR animals following challenge with 
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hypoxia (Panel C) or methacholine (Panel D).  In all cases, incubation of vessels with NDGA abolished stimulus-
induced vascular release of 12(S)- or 15(S)-HETE.     
DISCUSSION 
 While the development of many cardiovascular disease risk factors is associated with profound 
alterations to vascular reactivity (9, 12, 18) and most commonly with impaired endothelium-dependent dilation 
(32), the development of hypercholesterolemia has somewhat less predictable effects on vasodilator responses.   
Impairments to numerous indices of endothelium-dependent dilation have been found in hypercholesterolemic 
humans (2, 6, 8, 20, 29, 39), but this is not universally observed (7, 34).  Additionally, while some animal 
models of hypercholesterolemia have exhibited blunted patterns of endothelium-dependent dilation (41, 42), 
studies have also suggested that these impairments can be mild (17, 24, 47), if they are present at all (46).  
Given this lack of clarity within the existing literature, the present study was designed to evaluate the impact of 
genetic hypercholesterolemia in mice on endothelium-dependent and independent dilation of skeletal muscle 
resistance arterioles. 
 The primary observation of this study was that dilator reactivity of skeletal muscle resistance arterioles 
of ApoE and LDLR mice was not strikingly different from that determined in C57 control animals.  As evident 
from Figure 1, dilator reactivity to the endothelium-dependent stimuli of hypoxia and acetylcholine, while 
somewhat blunted, were largely intact in arterioles from both ApoE and LDLR mice.  Further, responses to the 
endothelium-independent stimuli of PGI2 and the NO donor sodium nitroprusside were also generally intact, 
and manifested only mild reductions in the magnitude of dilation, if they were present at all.  When combined 
with observations of arteriolar wall mechanics presented in Figure 2, wherein the present results suggest that 
passive expansion of arteriolar diameter with elevated intralumenal pressure was blunted in ApoE and LDLR 
mice – resulting in a mild (but not statistically significant) reduction in incremental distensibility – the present 
results support three initial conclusions: 1) endothelial function, with regard to net dilator reactivity, is largely 
intact in skeletal muscle resistance arterioles of ApoE and LDLR mice, 2) vascular smooth muscle reactivity to 
exogenously supplied prostacyclin and nitric oxide appears to be near normal in these microvessels, and 3) 
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impairments to dilator reactivity at this stage may partially reflect developing alterations to the mechanics of the 
arteriolar wall rather than simply compromised endothelial or vascular smooth muscle function. 
 The data presented in Figures 3 and 4 suggest that, while the net dilator reactivity of individual 
arterioles in response to hypoxia and increasing acetylcholine concentration remains largely intact in ApoE and 
LDLR in comparison to C57, the predominant signaling molecules which contribute to this reactivity may be 
substantially altered.  Specifically, these results suggest that the portion of hypoxia- or acetylcholine-induced 
dilation that is mediated by endothelium-dependent generation of NO in C57 is lost with the development of 
hypercholesterolemia.  This interpretation is supported by observations that the impact of L-NAME on dilator 
reactivity of isolated arterioles in response to hypoxia or challenge with acetylcholine was nearly abolished in 
ApoE and LDLR, and that the stimulus-induced generation of nitric oxide from either hypoxia or methacholine 
was profoundly attenuated in arteries of hypercholesterolemic mice.  The loss of vascular NO bioavailability 
with profound hypercholesterolemia has been reported previously (21, 23), and these results support those of 
previous studies.  In contrast, the contribution of endothelium-derived prostacyclin to both hypoxia- and 
acetylcholine-induced dilation was not substantially impacted by development of the hypercholesterolemic 
condition in ApoE and LDLR.  This was evident in both the consistent impact of indomethacin on dilator 
responses across the three strains of mice and the comparable level of 6-keto-PGF1α production in arteries of 
C57, ApoE and LDLR in response to challenge with either hypoxia or methacholine.   Notably, the results of 
these experiments suggest that the arteriolar dilator response to reduced oxygen tension or increased 
acetylcholine challenge in C57 mice was overwhelmingly the result of the production and release of 
endothelium-derived nitric oxide and prostacyclin.  However, in both ApoE and LDLR models of 
hypercholesterolemia, significant dilator reactivity to both hypoxia and acetylcholine remained despite 
pharmacological inhibition of both nitric oxide synthase and cyclooxygenase with L-NAME and indomethacin, 
respectively.  These observations implicate the emergence of an additional dilator signaling pathway which may 
compensate for the loss of vascular nitric oxide bioavailability during hypercholesterolemia.   
76
Hypercholesterolemia and vascular reactivity 
  
 Previous studies have suggested that metabolites of arachidonic acid produced via either the ω-
hydroxylation (producing 20-HETE) or epoxygenation (producing EETs) reactions of cytochrome P450 
enzymes can contribute to arteriolar dilation in response to both hypoxia (14) and acetylcholine (28).  However, 
results from the present study suggest that this is not the case in skeletal muscle resistance arterioles from C57 
control mice or with the development of hypercholesterolemia in either ApoE or LDLR mice.  Treatment of 
arterioles with 17-ODYA, either alone or in combination with L-NAME and indomethacin, had no impact on 
dilator responses to hypoxia or increased concentration of acetylcholine in any of the three mouse strains.   
 It has previously been demonstrated that the development of diet-induced hypercholesterolemia in 
rabbits may result in an increased role for lipoxygenase metabolites in contributing to endothelium-dependent 
dilator reactivity (35).   To address the possibility that products of arachidonic acid metabolized through 
lipoxygenases may contribute to the residual dilation to hypoxia and acetylcholine in ApoE and LDLR 
following treatment with L-NAME and indomethacin, arterioles were treated with NDGA, either alone or in 
combination with L-NAME and indomethacin (Figure 6).  While NDGA had no significant impact on dilator 
reactivity in C57, it blunted dilator responses to hypoxia and acetylcholine in arterioles from ApoE and LDLR 
when given alone, and abolished responses in arterioles from these strains when given following pre-treatment 
with L-NAME and indomethacin.  These results provided compelling evidence that the generation of 
metabolites of arachidonic acid via lipoxygenase may provide a compensatory mechanism to maintain arteriolar 
dilator reactivity in ApoE and LDLR.  In support of this concept, data presented in Figure 7 provided evidence 
that vascular production of 12(S)-HETE and 15(S)-HETE, from 12- and 15-lipoxygenase, respectively, 
although minimal in C57 in response to either hypoxia or methacholine challenge, was profoundly elevated in 
arteries of both ApoE and LDLR following exposure to both of these stimuli.   
 Recent studies have provided some compelling insight into the patterns of arteriolar reactivity in mice 
with diet-induced hypercholesterolemia.  In wild type mice, two weeks of high cholesterol diet has previously 
been demonstrated to result in an impaired dilator reactivity of cremasteric arterioles (in situ) to 10-5 M 
acetylcholine (41).  However, additional study from Kim et al. (24) suggested that the impairments to arteriolar 
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dilation with diet-induced hypercholesterolemia in wild type mice may be a function of the arteriolar proximity 
to a paired venule, as the degree of dilator impairment was inversely proportional to diffusion distance from the 
venule.  Interestingly, both of these studies have provided evidence that the dysfunction may be most tightly 
predicted by profound elevations in oxidant stress (24, 41) and elevations in P-selectin mediated cellular 
adhesion (24).  The results from these previous studies may provide compelling avenues for future study.  
 Throughout these studies, the production of vasodilator metabolites in response to challenge with either 
hypoxia or methacholine was determined from larger conduit arteries or aortic segments.  These data were then 
employed to provide insight into the mechanical responses of skeletal muscle resistance arterioles following 
exposure to either reductions in oxygen tension or challenge with acetylcholine.  As a result, these results 
should be interpreted with some caution, as mechanisms underlying vascular reactivity in response to specific 
stimuli are not necessarily consistent across all vessels and can demonstrate considerable heterogeneity.  
Ongoing studies will be needed to determine if the present results acquired using conduit arteries are 
maintained in the peripheral microcirculation. 
 Taken together, the results of the present study suggest that with the development of genetic 
hypercholesterolemia in ApoE and LDLR mice, the dilator reactivity of skeletal muscle resistance arterioles is 
largely intact, although the signaling mechanisms responsible for these responses are altered.  While the 
contribution of prostacyclin to endothelium-dependent dilation appears to be maintained, vascular levels of 
nitric oxide bioavailability are dramatically reduced.  However, with the development of hypercholesterolemia, 
the production of dilator metabolites via 12- and 15-lipoxygenase emerges as a compensatory mechanism in 
ApoE and LDLR, and help to maintain net dilator reactivity in these vessels despite the loss of components 
dependent on nitric oxide bioavailability.  Focused effort into the signaling mechanisms responsible for the 
reduction in vascular nitric oxide bioavailability and the progressive compensation for this loss by 
lipoxygenases may represent exciting avenues for future investigation.  Additionally, the consequences of both 
the chronic reductions in nitric oxide bioavailability and the increased generation of arachidonic acid 
metabolites via lipoxygenases for other microvascular outcomes (e.g., microvessel network structure, wall 
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mechanics, anti-thrombotic processes, spatio-temporal regulation of perfusion) will also require considerable 
future study. 
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Table 1.  Baseline characteristics of mice and individual arterioles used in the present study.  * p<0.05 vs. C57; † 
p<0.05 vs. ApoE.      
 
  C57 ApoE  LDLR  
Mass (g) 32±1 34±1 31±1 
MAP (mmHg) 85±2 89±3 102±4* 
[Glucose]blood (mg/dl) 91±5 108±10 117±6* 
[Insulin]plasma (ng/ml) 1.2±0.2 1.5±0.8 3.1±0.6* 
[Total Cholesterol]plasma (mg/dl) 90±10 302±19* 425±29*† 
[LDL Cholesterol]plasma (mg/dl) 52±6 285±15* 396±24*† 
[Triglycerides]plasma (mg/dl) 86±6 188±15* 124±14*† 
    
Inner Diameter – Active (μm) 59±4 54±3 56±4 
Inner Diameter – Passive (μm) 155±5 146±5 133±7* 
Active Tone (%) 61±4 63±4 58±4 
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FIGURE LEGENDS 
Figure 1.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57, ApoE and 
LDLR mice in response to hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B), sodium 
nitroprusside (Panel C) and prostacyclin (Panel D).    Data, presented as mean±SEM, are shown for arterioles under 
control conditions and for endothelium-dependent stimuli (hypoxia and acetylcholine), following removal of the 
vascular endothelium (please see text for details).  n=8 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs. 
control within that strain. 
 
Figure 2.  Data, presented as mean±SEM, describing intralumenal pressure-induced expansion (Panel A) and 
arteriolar wall incremental distensibility (Panel B) of isolated skeletal muscle microvessels from C57, ApoE and 
LDLR mice under passive (Ca2+-free) conditions.  n=8 animals for each group; * p<0.05 vs. C57. 
 
Figure 3.  Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57, ApoE and 
LDLR mice in response to hypoxia (Panel A) and increasing concentrations of acetylcholine (Panels B-D).  Data, 
presented as mean±SEM, are shown for arterioles under control conditions, and following pharmacological 
inhibition of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined 
inhibition of both enzymatic pathways (please see text for details).  n=5-10 animals for each group; * p<0.05 vs. 
control conditions, † p<0.05 vs. no response. 
 
Figure 4.  Data describing the production of nitric oxide (from aortae) or 6-keto-PGF1α (from pooled arteries) of 
C57, ApoE and LDLR in response to hypoxia (Panels A and C, respectively) or increasing concentrations of 
methacholine (Panels B and D, respectively).  Data, presented as mean±SEM, are shown under control conditions, 
and following pharmacological inhibition of NO synthase with L-NAME or cyclooxygenase with indothemation 
(INDO), as appropriate.  n=8 animals for each group, with each n representing either an aortae or pooled arteries 
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from an individual mouse; please see text for details.  * p<0.05 vs. respective control; † p<0.05 vs. C57 under that 
condition; ‡ vs. ApoE under that condition. 
 
Figure 5.  Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57, ApoE and 
LDLR mice in response to hypoxia (Panel A) and increasing concentrations of acetylcholine (Panels B-D).  Data, 
presented as mean±SEM, are shown for arterioles under control conditions, and following pharmacological 
inhibition of cytochrome P450 enzymes with 17-ODYA, either alone or in combination with L-NAME and 
indothemation (INDO).  n=6-7 animals for each group; * p<0.05 vs. control conditions in that strain; † p<0.05 vs. 
treatment with 17-ODYA alone; ‡ p<0.05 vs. no response. 
 
Figure 6.  Data, presented as mean±SEM, describing the dilator responses of isolated skeletal muscle resistance 
arterioles of C57, ApoE and LDLR mice in response to hypoxia (Panel A) and increasing concentrations of 
acetylcholine (Panels B-D).  Data are shown for arterioles under control conditions, and following pharmacological 
inhibition of lipoxygenase enzymes with NGDA, either alone or in combination with L-NAME and indothemation 
(INDO).  n=6-7 animals for each group; * p<0.05 vs. control conditions; † p<0.05 vs. treatment with NDGA alone. 
 
Figure 7.  Data describing the production of 12(S)-HETE or 15(S)-HETE from pooled arteries of C57, ApoE and 
LDLR in response to hypoxia (Panels A and C) or increasing concentrations of methacholine (Panels B and D).   
Data, presented as mean±SEM, are shown for arteries under control conditions, and following pharmacological 
inhibition of lipoxygenases with NDGA.  n=6 animals for each group, with each n representing pooled arteries from 
an individual mouse; please see text for details.  * p<0.05 vs. respective control; † p<0.05 vs. C57 under that 
condition. 
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ABSTRACT 
Objective: To determine if arachidonic acid (AA)-induced skeletal muscle arteriolar dilation is altered 
with hypercholesterolemia in ApoE and LDLR gene deletion mice fed normal diet.  This study also 
determined contributors to altered AA-induced dilation between dyslipidemic mice and controls; 
C57/Bl/6J (C57). 
Methods: Gracilis muscle arterioles were isolated, with mechanical responses assessed following 
challenge with AA under control conditions and after elements of AA metabolism pathways were 
inhibited.  Conduit arteries from each strain were used to assess AA-induced production of PGI2 and 
TxA2. 
Results: Arterioles from ApoE and LDLR exhibited a blunted dilation to AA versus C57.  While 
responses were cyclooxygenase-dependent in all strains, inhibition of thromboxane synthase or blockade 
of PGH2/TxA2 receptors improved dilation in ApoE and LDLR only.  AA-induced generation of PGI2 
was comparable across strains, although TxA2 generation was increased in ApoE and LDLR.  Arteriolar 
reactivity to PGI2 and TxA2 was comparable across strains.  Treatment with TEMPOL improved dilation 
and reduced TxA2 production with AA in ApoE and LDLR.  
Conclusions: These results suggest that AA-induced arteriolar dilation is constrained in ApoE and LDLR 
via an increased production of TxA2.  While partially due to elevated oxidant stress, additional 
mechanisms contribute which are independent of acute alterations in oxidant tone. 
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INTRODUCTION 
 Dyslipidemia, and specifically hypercholesterolemia, has repeatedly been demonstrated to represent a 
strong predisposing risk factor for the development of coronary and peripheral arterial disease (1).  While this 
increased risk for the progression of vascular disease with hypercholesterolemia is most commonly associated 
with an increased predisposition for the development of atherothromboses, atherosclerotic lesions and plaque 
depositions (3, 10, 26), investigations into the impact of hypercholesterolemia on vascular reactivity and 
endothelial function, potentially as contributing mechanisms to vascular disease, is less clearly understood.   
 While some disparity in the prevailing literature exists (25), the general consensus is that the 
development of hypercholesterolemia is usually associated with a significant reduction in the bioavailability 
of endothelium-derived nitric oxide (5, 6, 23), with the relatively predictable ensuing outcome of an impaired 
vascular reactivity in response to stimuli that are considered to have a significant contribution from this 
signaling molecule/pathway (i.e., flow-mediated dilation; ref. 12).  In our recent study, we provided evidence 
suggesting that development of familial hypercholesterolemia (a genetic disorder resulting in exceptionally 
high low density lipoprotein [LDL] level, in the face of an otherwise relatively normal lipid profile) in the 
LDL receptor gene deletion mouse or type III hyperlipidemia (a condition wherein both LDL and plasma 
triglycerides are significantly elevated) in the apolipoprotein E gene deletion mouse, was associated with a 
near complete abolition of the bioavailability of endothelium-derived nitric oxide in response to imposed 
stimuli (22).  However, this loss of vascular nitric oxide bioavailability did not result in a profound reduction 
in dilator reactivity, as an increased generation of dilator signaling molecules through 12/15 lipoxygenases 
emerged with evolution of the dyslipidemia (22), suggesting that alterations to the metabolism of arachidonic 
acid may be associated with hypercholesterolemia, and that these can have profound consequences for 
vascular function.     
 In 1996, the work of Pfister and colleagues (16, 17) strongly suggested that diet-induced 
hypercholesterolemia in rabbits can lead to changes in arachidonic acid metabolism, mediated via 
lipoxyegnase are cytochrome P450 epoxygenase enzymes, causing profound alterations to dilator reactivity 
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determined in isolated aortic segments.  Additionally, Srisawat et al. (21), while providing additional 
evidence that diet-induced hypercholesterolemia results in impaired endothelium-dependent dilation in aortic 
rings, determined that chronic treatment with indomethacin improved endothelial function, and was 
associated with reductions in urinary levels of 2,3-dinor-thromboxane B2 and 8-iso-PGF2α, a stable urinary 
breakdown product of thromboxane A2 and a marker of chronic oxidant stress, respectively.  Most recently, 
Pfister demonstrated that impairments to endothelium-dependent dilation in aortic rings of 
hypercholesterolemic rabbits were diminished in a subgroup of animals lacking a functional thromboxane 
receptor (15).  These previous results suggest that a contributing mechanism underlying alterations to vascular 
reactivity under conditions of hypercholesterolemia may involve both elevated vascular oxidant stress and 
metabolism of arachidonic acid through cyclooxygenase pathways.  However, given recent observations in 
our laboratory (22) and by others (25) suggesting that alterations to endothelium-dependent reactivity may 
reflect the specific challenge imposed rather than a global impairment, we examined alterations to dilator 
reactivity in response to direct challenge with arachidonic acid itself, wherein the bioavailability of 
endothelium-derived nitric oxide is not a significant contributing element to the net mechanical response.  
Using both apolipoprotein E and LDL receptor gene deletion mouse models of hypercholesterolemia, the 
hypothesis tested in the present study was that arachidonic acid-induced dilator reactivity of skeletal muscle 
arterioles would be impaired in the presence of profound dyslipidemia and that this would be the result of 
alterations to either the production or vascular reactivity to metabolites of arachidonic acid via 
cyclooxygenase, owing to the presence of an elevated oxidant stress.   
MATERIALS AND METHODS 
Animals:  The present study used three strains of mice, the C57/Bl/6J (C57) as the control strain and the 
apolipoprotein E gene deletion (B6.129P2-Apoetm1Unc/J; ApoE) and low density lipoprotein receptor gene 
deletion (B6.129S7-Ldlrtm1Her/J; LDLR) mice on the C57/Bl/6J background.  All mice were purchased 
from Jackson Laboratories (Bar Harbor, ME) at 6 weeks of age.  The ApoE mouse manifests type III 
hyperlipidemia, in which both plasma cholesterol and triglyceride levels are elevated, although the 
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elevations in LDL are not as severe as in the LDLR gene deletion mouse (19). In contrast, the LDLR 
mouse is a model of human familial hypercholesterolemia, manifesting a profound increase in serum LDL 
levels while ingesting a normal diet (11). 
 Male mice of each strain were fed standard chow and drinking water ad libitum and were housed in 
an AAALAC-accredited animal care facility at the West Virginia University Health Sciences Center and all 
protocols received prior IACUC approval.  At 20 weeks of age, after an overnight fast, mice were 
anesthetized with injections of sodium pentobarbital (50 mg•kg-1 i.p.), and received tracheal intubation to 
facilitate maintenance of a patent airway.  In all mice, a carotid artery was cannulated for determination of 
arterial pressure.  Blood aliquots were drawn from the jugular vein cannula for determination of glucose and 
insulin (Linco), a lipid profile (Waco), and nitrotyrosine (Oxis).   
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the intramuscular 
continuation of the right gracilis artery was removed and cannulated, as described previously (8).  These 
first order arterioles were extended to their approximate in situ length and were equilibrated at 80% of the 
animal's mean arterial pressure in order to approximate the in vivo intralumenal pressure experienced by 
the animal (13).  Following equilibration, arteriolar reactivity was evaluated in response to increasing 
concentrations of arachidonic acid (10-10 M – 10-6 M; Sigma).  Additionally, in select experiments 
arteriolar reactivity was also evaluated in response to increasing concentrations of prostacyclin (PGI2; 10-
10 M – 10-6 M; Biomol) or carbocyclic thromboxane A2 (TxA2; 10-10 M – 10-6 M; Cayman).   
 Removal of the arteriolar endothelium was accomplished by passing an air bolus through the 
perfusate line into the isolated microvessel, the efficacy of which was determined from a loss of all dilator 
reactivity in response to application of 10-6 M acetylcholine (8).  To assess the contribution of nitric oxide 
production or the generation of metabolites via cyclooxygenase as mediators of arteriolar reactivity, 
isolated vessels were treated with the nitric oxide synthase inhibitor L-NG-nitroarginine methyl ester (L-
NAME; 10-4 M for 45 minutes prior to agonist challenge; Sigma) or the cyclooxygenase antagonist 
indomethacin (INDO; 10-6 M for 60 minutes prior to agonist challenge; Sigma), respectively.  To 
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determine the contribution of metabolites of arachidonic acid mediated via cytochrome P450 enzymes, 
vessels were treated with the suicide substrate inhibitor 17-octadecynoic acid (17-ODYA; 10-5 M for 60 
minutes prior to agonist challenge; Sigma).  Previous studies have demonstrated that 17-ODYA 
profoundly attenuates both the ω-hydroxylation (producing 20-hydroxyeicosatetraenoic acid; 20-HETE) 
and epoxygenation (producing epoxyeicosatrienoic acids; EETs) reactions of arachidonic acid through 
cytochrome P450 (24), thus preventing changes to vascular levels of 20-HETE or EETs as contributing 
mediators to endothelium-dependent dilation.   To assess the contribution of lipoxygenase metabolites to 
the patterns of arteriolar dilation, vessels were treated with nordihydroguaiaretic acid (NDGA; 3×10-5 M 
for 45 minutes prior to agonist challenge; Biomol), a selective inhibitor of 12/15-lipoxygenases (20, 27).  
To antagonize vascular PGH2/TxA2 receptors, vessels were treated with SQ-29548 (10-5 M for 30 minutes 
prior to agonist challenge; Biomol), while inhibition of thromboxane synthase was accomplished using 
carboxyheptyl imidazole (CHI; 10-5 M for 45 minutes prior to agonist challenge; Biomol).    To reduce 
vascular oxidant tone, arterioles were treated with 4-Hydroxy-2,2,6,6-tetramethylpiperidine-1-15N-oxyl 
(TEMPOL; 10-4M for 60 minutes prior to agonist challenge, Sigma). 
Determination of Vascular Metabolites of Arachidonic Acid:  Vascular production of 6-keto-prostaglandin 
F1α (6-keto-PGF1α; the stable breakdown product of PGI2; ref. 14), and 11-dehydro-thromboxane B2 (11-
dehydro-TxB2; the stable plasma breakdown product of TxA2; ref. 4) in response to challenge with 
arachidonic acid within the three mouse strains was assessed using pooled conduit arteries (femoral, 
saphenous, iliac, carotid arteries) from each mouse.  Vessels were incubated in microcentrifuge tubes in 1 ml 
of physiological salt solution for 30 minutes under control conditions (21% O2), after which time arachidonic 
acid (10-6 M) was added to the tube for an additional 30 minutes.  After the second 30 minute period, the PSS 
was transferred to a new tube, frozen in liquid N2 and stored at -80°C.  Metabolite release by the vessels was 
determined using commercially available EIA kits for 6-keto-PGF1α and 11-dehydro-TxB2 (Cayman). 
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Data and Statistical Analyses:  Active tone of individual arterioles at the equilibration pressure was 
calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to Ca2+-free PSS, 
and Dmax is the maximum diameter measured at the equilibration pressure in Ca2+-free PSS.   
 Dilator responses of isolated arterioles following challenge with dilator agonists were fit with the 
three-parameter logistic equation: 
⎥⎦
⎤⎢⎣
⎡
+
−+= −xEDy 50log101
minmaxmin  
where y  represents the change in arteriolar diameter, “min” and “max” represent the lower and upper 
bounds, respectively, of the change in arteriolar diameter with increasing agonist concentration, x  is the 
logarithm of the agonist concentration and 50log ED  represents the logarithm of the agonist concentration ( x ) 
at which the response ( y ) is halfway between the lower and upper bounds.     
 Data are presented as mean±SEM.  Statistically significant differences in measured and calculated 
parameters in the present study were determined using analysis of variance (ANOVA).  In all cases, Student-
Newman-Keuls post hoc test was used when appropriate and p<0.05 was taken to reflect statistical 
significance.   
RESULTS 
 Table 1 presents baseline characteristics of the mouse groups in the present study.  While all mice 
were of similar mass at 20 weeks of age, LDLR experienced a significant elevation in mean arterial pressure 
and fasting insulin concentration versus values in C57 or ApoE.   Additionally, both ApoE and LDLR 
manifested a profound hypercholesterolemia, most severe in LDLR.  Further, ApoE exhibited a significant 
hypertriglyceridemia as well, while plasma triglyceride levels in LDLR were not different from that in C57.  
Finally, plasma levels of nitrotyrosine, a marker of chronic elevations in oxidant stress, were significantly 
elevated in ApoE and LDLR as compared to C57.  With regard to basal vascular tone, isolated arterioles from 
all mouse groups demonstrated a comparable resting active diameter and passive (calcium-free) diameter, 
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such that no significant difference in active tone was calculated between C57, ApoE and LDLR in the present 
study. 
 Data summarizing the dilator responses of skeletal muscle resistance arterioles from C57, ApoE and 
LDLR in response to challenge with increasing concentrations of arachidonic acid are presented in Figure 1.  
Under control conditions, the reactivity of arterioles from ApoE and LDLR, while not significantly different 
from each other, both demonstrated a reduction in their maximum bound as compared to responses in 
arterioles from C57.  Endothelium-denudation via perfusion with an air bolus eliminated mechanical 
responses of vessels across the three strains in response to application of arachidonic acid. 
 The effects of pharmacological blockade of lipoxygenases and cyclooxygenases with NDGA and 
INDO, respectively, on arachidonic acid-induced vasodilation in isolated arterioles are summarized in Figure 
2.  In arterioles from C57 (Panel A), blockade of lipoxygenases with NDGA had no impact on dilator 
responses to arachidonic acid, while treatment with indomethacin abolished all dilation to arachidonic acid.  
Arterioles from ApoE, while demonstrating a blunted overall reactivity to arachidonic acid, also experienced 
a severe reduction in dilator reactivity following cyclooxygenase inhibition with indomethacin (Panel B).  
However, while treatment with NDGA alone did not impact arachidonic acid-induced dilation in vessels from 
ApoE, application of NDGA to vessels that had been treated with indomethacin eliminated the residual 
dilation in response to arachidonic acid that remained following cyclooxygenase inhibition alone.  Finally, 
arterioles from LDLR appeared to demonstrate a dilator response to arachidonic acid challenge that was 
dependent on the production of metabolites generated via both lipoxygenases and cyclooxygenases, as 
antagonists to these pathways given in isolation resulted in modest reductions to the compromised level of 
reactivity, while treatment with both NDGA and indomethacin abolished all arachidonic acid-induced 
reactivity (Panel C).  Treatment of isolated arterioles from C57, ApoE or LDLR with either L-NAME or 17-
ODYA did not result in either significant or consistent effects of dilator responses following challenge with 
increasing concentrations of arachidonic acid (data not shown). 
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 Figure 3 presents the effects of antagonizing thromboxane A2 generation (with CHI) and action (with 
SQ-29548) on dilator responses of skeletal muscle arterioles in the present study.  In control animals, 
application of either CHI or SQ-29548 had no impact on arteriolar dilation in response to increasing 
concentrations of arachidonic acid (Panel A).  In contrast, arterioles from both ApoE (Panel B) and LDLR 
(Panel C) exhibited a significant improvement to their degree of arachidonic acid-induced dilation relative to 
untreated conditions following either inhibition of thromboxane synthase with CHI or blockade of the 
PGH2/TxA2 receptor (SQ-29548). 
  Data describing the arachidonic acid-induced generation of the cyclooxygenase products PGI2 
(estimated from levels of 6-keto-PGF1α) and TxA2 (estimated from levels of 11-dehydro TxB2) from pooled 
arteries of the three mouse groups in the present study are summarized in Figure 4.  Following application of 
10-6 M arachidonic acid, arteries from C57, ApoE and LDLR all demonstrated a significant increase in PGI2 
release, the degree of which was comparable between the three mouse strains (Panel A).  In contrast, 
arachidonic acid-induced generation of TxA2, while statistically significant in arteries from C57, 
demonstrated a substantially more robust response in vessels from both ApoE and LDLR (Panel B).  Pre-
treatment of pooled vessels with either CHI or indomethacin severely attenuated all arachidonic acid-induced 
TxA2 generation in all three strains. 
 Arteriolar reactivity in response to challenge with prostacyclin (Panel A) or carbocyclic thromboxane 
A2 (Panel B) in the three mouse groups is summarized in Figure 5.  In response to increasing concentrations 
of prostacyclin, arterioles from C57 and ApoE demonstrated a very similar degree of dilator reactivity, 
although this response demonstrated a trend toward impairment in vessels from LDLR as compared to that in 
vessels from either other strain (Panel A).  Arterioles from all three mouse strains exhibited very similar 
patterns of constrictor reactivity in response to challenge with increasing concentrations of carbocyclic 
thromboxane A2 (Panel B). 
 Figure 6 presents the effects of treating vessels with the antioxidant TEMPOL, the thromboxane 
synthase inhibitor CHI, or both, on arteriolar responses to increasing concentrations of arachidonic acid.  
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Addition of TEMPOL did not have a significant impact on arteriolar diameter in vessels from any of the three 
mouse strains under resting conditions.  In arterioles from C57 (Panel A), neither treatment with TEMPOL 
nor CHI had a significant impact on dilator reactivity to arachidonic acid.  In contrast, for arterioles from both 
ApoE (Panel B) and LDLR (Panel C), treatment with either TEMPOL or CHI significantly improved dilator 
responses to arachidonic acid, with the effects of CHI being stronger than that for TEMPOL.  Interestingly, in 
both ApoE and LDLR, combined treatment with CHI and TEMPOL did not have any effect on arachidonic 
acid-induced dilation beyond that determined for CHI treatment alone.  
 Figure 7 presents data describing the effects of treating arteries from C57, ApoE or LDLR with 
TEMPOL on arachidonic acid-induced thromboxane A2 production.  While treatment with the antioxidant 
had an insignificant impact on vascular thromboxane production in C57, incubation of vessels with TEMPOL 
significantly reduced the arachidonic acid-induced production of TxA2 in both ApoE and LDLR.  However, 
this reduction in thromboxane generation was only partial in nature, and levels of TxA2 production in 
response to challenge with arachidonic acid following treatment with TEMPOL remained significantly 
increased versus that in untreated arteries from ApoE and LDLR.  
DISCUSSION 
 Although hypercholesterolemia represents a powerful risk factor for the development of peripheral 
artery disease (1), the effects of hypercholesterolemia on vascular reactivity and endothelial function is less 
clearly understood.  Given recent studies suggesting that diet-induced hypercholesterolemia can alter 
arachidonic acid metabolism and profoundly impact vascular reactivity through signaling mechanisms 
associated with the generation of thromboxane A2 (15, 18, 21), the present study determined the effects of 
genetic hypercholesterolemia on the dilator reactivity of skeletal muscle resistance arterioles in response to 
challenge with arachidonic acid.  More specifically, the hypothesis tested in this study was that arachidonic 
acid-induced arteriolar dilation in ApoE and LDLR would be impaired owing to either the production of, or 
vascular reactivity to, metabolites of arachidonic acid via cyclooxygenase, and that these alterations would be 
associated with an elevated oxidant stress. 
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 Contrary to our results with dilator stimuli that are more strongly dependent on the bioavailability of 
endothelium-derived nitric oxide, where reactivity was largely maintained in the face of a profound reduction 
in this parameter (22), the results presented in Figure 1 indicate that skeletal muscle arteriolar dilation in 
response to increasing concentrations of arachidonic acid was significantly reduced in both ApoE and LDLR 
as compared to responses determined in C57.  Interestingly, the data presented in this figure also strongly 
suggest that not only is the overwhelming majority of dilator reactivity in response to arachidonic acid 
dependent on a functional endothelium in control animals, the impairments to arteriolar dilation with this 
stimulus may also originate with alterations to endothelial function, rather than within vascular smooth 
muscle.   
 While results from the present study did not demonstrate a role for either nitric oxide bioavailability or 
for metabolites of arachidonic acid mediated via cytochrome P450 enzymes in terms of contributing to the 
arachidonic acid-induced dilator reactivity of skeletal muscle arterioles in any of the three mouse strains, 
activity mediated through cyclooxygenase (and to a lesser extent lipoxygenase) were critical.  While arteriolar 
dilation in response to arachidonic acid was mediated entirely via cyclooxygenase in vessels from C57, 
vessels from ApoE and LDLR demonstrated a dilator response that was increasingly a function of metabolites 
via both cyclooxygenase and lipoxygenase, with this effect being more pronounced in LDLR than in ApoE, 
where the response was still predominantly cyclooxygenase-dependent.  However, the data presented in 
Figure 2 do not provide significant insight into the impaired dilator reactivity demonstrated in arterioles of 
ApoE and LDLR in response to challenge with arachidonic acid beyond the critical involvement of 
cyclooxygenase.  Given previous studies suggesting that the development of the hypercholesterolemic 
condition can profoundly impact arachidonic acid metabolism in general (7, 18), and the recent studies from 
both Pfister (15) and Srisawat et al. (21) that implicate altered behavior mediated through thromboxane 
generation/action as contributing mechanism to altered patterns of vascular reactivity with 
hypercholesterolemia, we treated vessels from ApoE and LDLR with an inhibitor of thromboxane synthase 
(CHI) or an antagonist for the PGH2/TxA2 receptor (SQ-29548).  As shown in Figure 3, while neither of these 
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agents had a significant role in the dilator responses in arterioles from C57, application of either CHI or SQ-
29548 resulted in a significant improvement in the dilator responses of arterioles from ApoE or LDLR in 
response to challenge with increasing concentrations of arachidonic acid.  Interestingly, the ameliorative 
effect was comparable with either pharmacological agent.  While this implicates either increased 
thromboxane generation or an increased gain/sensitivity at the vascular thromboxane receptor as contributing 
mechanisms to the impaired arachidonic acid-induced arteriolar dilation, these data do not provide insight into 
which component may be most responsible.  However, these data do strongly suggest that the development of 
a thromboxane-sensitive component which may act to constrain arachidonic acid-induced arteriolar dilation 
accompanies the evolution of genetic hypercholesterolemia. 
 As both CHI and SQ-29548 elicited similar improvements to arteriolar dilation in response to 
arachidonic acid challenge in ApoE and LDLR, it was necessary to discern which processes contributed to the 
constrained dilator reactivity: 1) increasing thromboxane A2 production in response to arachidonic acid 
production, 2) increased vascular reactivity to produced thromboxane A2, or both.  The data presented in 
Figure 4 indicate that arachidonic acid-induced generation of PGI2 (estimated from 6-keto-PGF1α levels) 
remained intact in arteries of ApoE and LDLR as compared to that determined in C57, an observation that is 
consistent with previous studies in the coronary vasculature of ApoE mice (9).  In contrast, arachidonic-acid 
induced generation of thromboxane A2 (estimated from 11-dehydro-TxB2 levels) was significantly increased 
with the evolution of genetic hypercholesterolemia in ApoE and LDLR.  When taken together with data in 
Figure 5, which suggest that the sensitivity of resistance arterioles from ApoE and LDLR in response to 
increasing concentrations of either prostacyclin or thromboxane A2 is not dramatically altered from that 
determined for C57 control mice, these data may provide compelling evidence that a predominant 
contributing mechanism underlying the constrained arteriolar dilation with increasing concentrations of 
arachidonic acid may be the development of an increased generation of the constrictor prostanoid 
thromboxane A2, which antagonizes the dilator effects associated with the generation of prostacyclin. 
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 Given that previous studies have clearly demonstrated the critical role for elevated oxidant tone in the 
increased generation of thromboxane through cyclooxygenase in response to challenge with arachidonic acid 
(2, 28, 29), and our observations of an increase in the plasma levels of nitrotyrosine in the ApoE and LDLR as 
compared to that determined in C57, the data presented in Figures 6 and 7 provide some insight into the 
potential role that elevated vascular oxidant tone may play in the increased arachidonic acid-induced 
thromboxane A2 generation with genetic dyslipidemia.  While treatment with TEMPOL had no impact on 
arachidonic acid-induced dilation or TxA2 generation in arterioles from C57, it significantly improved the 
dilator response in microvessels from both ApoE and LDLR and reduced the levels of TxA2 production.  
However, in vessels from both strains, this improvement in dilator reactivity following treatment with the 
antioxidant was less pronounced than that determined following treatment with the inhibitor of thromboxane 
synthase, CHI.  Further, combined treatment with both TEMPOL and CHI did not result in an improvement 
beyond that determined with CHI treatment alone.  Additionally, while pre-treatment of pooled vessels with 
TEMPOL lowered arterial thromboxane production in response to challenge with arachidonic acid, the levels 
of thromboxane production remained significantly elevated despite the addition of the antioxidant.  Taken 
together these results suggest that, while an enhanced arachidonic acid-induced genesis of thromboxane A2 
via thromboxane synthase represents a strong contributor to the constrained dilator reactivity in skeletal 
muscle arterioles of ApoE and LDLR mice, the presence of an elevated vascular oxidant tone may represent a 
partial contributor to this shift in the metabolism of arachidonic acid.  Clearly, these results suggest that other 
parameters, independent of acute changes in vascular oxidant tone, also contribute to this increased generation 
of thromboxane A2.  Potential avenues for ongoing investigation in this regard can include the study of not 
only the effects of chronic elevations in vascular oxidant tone, but also the progression of a chronic state of 
inflammation associated with dyslipidemia (10, 26) and how these processes can ultimately impact pathways 
of arachidonic acid metabolism. 
 In summary, with the development of genetic hypercholesterolemia in ApoE and LDLR mice, the 
dilator reactivity of skeletal muscle resistance arterioles in response to increasing concentrations of 
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arachidonic acid is impaired.  This impairment does not appear to be associated with a reduction in the 
generation/release of, or an altered arteriolar reactivity to, prostacyclin.   However, with the evolution of this 
dyslipidemic condition, there appears to be an increase in the arachidonic acid-induced generation of the 
vasoconstrictor metabolite thromboxane A2.  While there does not appear to be an alteration to the arteriolar 
constrictor reactivity to thromboxane, the increased generation of this metabolite may compete with the 
dilator effects of prostacyclin, thus limiting net dilator reactivity in response to arachidonic acid.  Further, 
while an increase in vascular oxidant stress appears to contribute to this response, additional mechanisms 
which are independent of acute alterations to oxidant tone also contribute to this effect.    Future investigation 
will be required to discern which mechanistic alterations associated with the development of 
hypercholesterolemia contribute to the increased production of thromboxane A2, and what the implications of 
this shift in the metabolism of arachidonic acid are for issues such as the integrated control of tissue perfusion, 
tissue oxygenation and the protection from atherogenesis and atherothrombosis. 
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Table 1.  Baseline characteristics of mice and individual arterioles used in the present study.  * p<0.05 vs. 
C57; † p<0.05 vs. ApoE.      
 
  C57 ApoE  LDLR  
Mass (g) 33±2 34±2 33±2 
MAP (mmHg) 88±4 92±3 106±5*† 
[Glucose]blood (mg/dl) 84±7 103±11 115±7* 
[Insulin]plasma (ng/ml) 1.1±0.3 1.6±0.3 2.8±0.5* 
[Total Cholesterol]plasma (mg/dl) 88±9 288±17* 364±22*† 
[LDL Cholesterol]plasma (mg/dl) 49±5 260±11* 338±19*† 
[Triglycerides]plasma (mg/dl) 88±10 175±14* 116±18† 
Nitrotyrosineplasma (ng/ml) 14±5 54±11* 60±14* 
    
Inner Diameter – Active (μm) 54±4 55±5 51±4 
Inner Diameter – Passive (μm) 128±5 122±4 118±7 
Active Tone (%) 57±3 55±4 56±4 
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FIGURE LEGENDS 
Figure 1.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57, ApoE 
and LDLR mice in response to increasing concentrations of arachidonic acid.    Data, presented as 
mean±SEM, are shown for arterioles under control conditions and following removal of the vascular 
endothelium using air bolus perfusion (please see text for details).  n=6 animals for each strain; * p<0.05 vs. 
C57; † p<0.05 vs. control within that strain. 
 
Figure 2.  Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57 (Panel 
A), ApoE (Panel B) and LDLR (Panel C) mice in response to increasing concentrations of arachidonic acid.  
Data, presented as mean±SEM, are shown for arterioles under control conditions, and following 
pharmacological inhibition of cyclooxygenases with indomethacin, lipoxygenases with NDGA or combined 
inhibition of both enzymatic pathways (please see text for details).  n=5-10 animals for each group; * p<0.05 
vs. control conditions, † p<0.05 vs. no response. 
 
Figure 3.  Data describing the dilator responses of isolated skeletal muscle resistance arterioles of C57 (Panel 
A), ApoE (Panel B) and LDLR (Panel C) mice in response to increasing concentrations of arachidonic acid.  
Data, presented as mean±SEM, are shown for arterioles under control conditions, and following 
pharmacological inhibition of PGH2/TxA2 receptors with SQ-29548 and thromboxane synthase with CHI 
(please see text for details).  n=6-7 animals for each group; * p<0.05 vs. control conditions. 
 
Figure 4.  Data describing the arterial production of prostacyclin (as 6-keto-PGF1α; Panel A) or thromboxane 
A2 (as 11-dehydro TxB2; Panel B) from C57, ApoE and LDLR in response to 10-6 M arachidonic acid.  Data, 
presented as mean±SEM, are shown under control conditions, and following pharmacological inhibition of 
cyclooxygenase with indomethacin or thromboxane synthase (with CHI), as appropriate.  n=8 animals for 
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each group, with each n representing pooled arteries from an individual mouse; please see text for details.  * 
p<0.05 vs. respective control; † p<0.05 vs. C57 under that condition; ‡ vs. ApoE under that condition. 
 
Figure 5.  Data (mean±SEM) describing the reactivity of isolated skeletal muscle resistance arterioles of C57, 
ApoE and LDLR mice in response to increasing concentrations of prostacyclin (Panel A) or carbocyclic 
thromboxane A2 (Panel B).  n=6 animals for each group, no significant differences were identified in the 
vascular reactivity in response to increasing concentrations of prostacyclin or thromboxane A2. 
 
Figure 6.  Data, presented as mean±SEM, describing the dilator responses of isolated skeletal muscle 
resistance arterioles of C57 (Panel A), ApoE (Panel B) and LDLR (Panel C) mice in response to increasing 
concentrations of arachidonic acid.  Data are shown for arterioles under control conditions, following 
treatment of vessels with the antioxidant TEMPOL, following pharmacological inhibition of thromboxane 
synthase with CHI, and following treatment with both TEMPOL and CHI.  n=8-10 animals for each group; * 
p<0.05 vs. control conditions; † p<0.05 vs. treatment with TEMPOL alone. 
 
Figure 7.  Data describing the arterial production of thromboxane A2 (as 11-dehydro TxB2; Panel B) from 
C57, ApoE and LDLR in response to 10-6 M arachidonic acid.  Data, presented as mean±SEM, are shown 
under control conditions, and following treatment of pooled arteries with the antioxidant TEMPOL (10-4 M).  
n=6 animals for each group, with each n representing pooled arteries from an individual mouse; please see 
text for details.  * p<0.05 vs. within-strain/no arachidonic acid; † p<0.05 vs. within-strain/with arachidonic 
acid. 
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ABSTRACT 
Hypercholesterolemia is defined as excessively high plasma cholesterol levels, and is a strong 
risk factor for many negative cardiovascular events. Total cholesterol levels above 200 mg/dl have 
repeatedly been correlated as an independent risk factor for development of peripheral vascular (PVD) 
and coronary artery disease (CAD). With specific relevance to the microcirculation, it has been clearly 
demonstrated that evolution of hypercholesterolemia is associated with endothelial cell dysfunction, a 
near-complete abrogation in vascular nitric oxide bioavailability, elevated oxidant stress, and the 
creation of a strongly pro-inflammatory condition; symptoms which can culminate in profound 
impairments/alterations to vascular reactivity.  Considerable attention has been directed toward 
evaluating mechanisms and compensatory mechanisms by which hypercholesterolemia may impair 
microvascular endothelium dependent dilation. Clinically relevant pharmaceutical treatment options 
include therapies which decrease circulating cholesterol by preventing either formation in the liver or 
absorption in the intestine also have pleiotropic effects with may directly improve peripheral vascular 
outcomes. Physical activity is known to decrease PVD/CAD risk factors, increase circulating levels of 
high density lipoprotein and improve both cardiac and vascular function. The mechanistic consequences 
of these treatments are not well understood within the realms of inflammation, oxidative stress, and 
vascular reactivity; therefore, the hypothesis of this study was to determine the effects of pharmaceutical 
treatment, exercise, and combined therapy to improve restore endothelium dependent microvascular 
reactivity, NO bioavailability, decrease in oxidant stress, and decrease the a pro-inflammatory phenotype 
within the condition of familial hypercholesterolemia. 
Arterioles from the low density lipoprotein receptor (LDLR) gene deletion male mouse models of 
hypercholesterolemia at 20 weeks of age show no significant improvement to any of the ameliorative 
therapies. Interestingly, the pharmaceutical only group shows a detriment to the endothelium dependent 
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dilation within the C57/Bl/6J (C57) controls, with no significant improvements to the anti-inflammatory 
or anti-oxidant profiles. While the exercise and combination therapy were able to improve the overall 
inflammatory and oxidant profiles with respect to CRP, MCP-1, RANTES, and nitrotyrosine. These 
results suggest that independent of any cholesterol lowering effects, within a normocholesterolemic 
population, prophylactic administration of cholesterol lowering pharmaceutical therapies may be 
detrimental to the endothelium dependent vascular reactivity. Additionally, exercise or combination 
therapy may provide the greatest benefit, due to the overall improvements in the anti-inflammatory and 
anti-oxidant profiles.        
INTRODUCTION 
As high total cholesterol levels are considered to be a major independent risk factor for 
development of peripheral vascular disease (PVD) and coronary artery disease (CAD), considerable 
attention has been directed toward evaluating the impact and mechanisms of cholesterol lowering 
therapies and alternative interventions for cardiovascular outcomes (10; 34). Data acquired by the 
National Health and Nutrition Examination Survey 2005–2006 found that the mean total serum 
cholesterol level for Americans, over the age of 20, was 199 mg/dL, just below the American Heart 
Association (AHA) recommended level of 200 mg/dL (1; 22). Unfortunately, 16% of adults were found 
to have total cholesterol levels of more than 240 mg/dL, this level is considered by the AHA to carry 
twice the cardiovascular risk of those individuals at the desired level (1; 22).  
With specific relevance to the microcirculation, it has been clearly demonstrated that 
hypercholesterolemia is associated with endothelial cell dysfunction, decreased nitric oxide 
bioavailability, elevated oxidant stress, and a strongly pro-inflammatory condition; symptoms which can 
culminate in profound impairments to vascular reactivity.  Previous studies in our laboratory have 
suggested that the signaling mechanisms responsible for dilator reactivity of skeletal muscle resistance 
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arterioles in hypercholesterolemic animals remains intact however altered due to a decreased availability 
of NO compared to control (16; 25; 37; 39; 42; 43; 50).  This reduction in the availability of NO within 
the hypercholesterolemic vasculature either by deficits in production (i.e. NOS inhibition) or due to 
increases in NO degradation (i.e. NO scavenge). With the progression of familial hypercholesterolemia 
there is a greater reliance on the arachidonic acid dilator metabolites via 12- and 15-lipoxygenase to 
maintain endothelium dependent reactivity (39).  Additionally, with the evolution of hypercholesterolemia, 
an increase in vascular oxidant stress leading to alterations in arachidonic acid metabolism has also been 
reported (12).  
Investigation into vascular consequences of chronic hypercholesterolemia, the mechanisms 
through which this occurs, and the potentially beneficial effects of ameliorative therapies have received 
considerable attention in recent years. Pharmaceutical therapies are currently the most commonly 
prescribed medication within the United States. Statins drugs can act to decrease cholesterol levels by 
preventing the formation of cholesterol in the liver or preventing the absorption of cholesterol via the 
intestine, while ezetimibe acts selectively to inhibit the absorption of cholesterol from the intestine (38). 
These drugs, when used in combination (ezetimibe/simvastatin; Vytorin) act together via 
complementary pathways to prevent cholesterol absorption from the intestine and hepatic production in 
patients with hypercholesterolemia. Long term co-administration of these drugs have been shown to 
reduce LDL blood cholesterol levels by 60% while concurrently raising HDL levels and limiting liver 
toxicity traditionally caused by statin treatment alone (6; 32).  
These are generally prescribed for the cholesterol lowering effects; however reports of additional 
independent pleiotropic effects include, but are not limited to reducing inflammation, decreasing ROS, 
and increasing NO bioavailability.  These pharmaceutical agents have been found to independently 
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improve endothelial function with respect to FMD, with 150% in normocholesterolemic and 180% in 
hypercholesterolemic patients who had also been diagnosed with peripheral artery disease (13).  
The AHA and American College of Sports Medicine (ACSM) have recently released joint 
guidelines recommending aerobic and resistance physical activities for individuals under the age of 65 to 
maintain health, reduce risk of chronic disease states, and manage current risk factors including 
hypercholesterolemia (14; 20; 40). Hypercholesterolemia has been shown to impair aerobic capacity by 
impairing dilator regulation, thought to be due to a lack of vascular reactivity stemming from a reduction 
in NO bioavailability (24). However acute and chronic exercise programs have been shown to improve 
vascular reactivity, reduce pro-inflammatory phenotypes, and improve the oxidant balance (5; 16; 28; 
30). 
However, the effects of these ameliorative therapies are not mechanistically well understood.  
Therefore, the purpose of the present study was to evaluate the vascular reactivity and determine the 
capacity of pharmaceutical treatment, exercise, and combined therapy to restore NO bioavailability, 
decrease in oxidant stress, and decrease the a pro-inflammatory phenotype within the condition of familial 
hypercholesterolemia.  
MATERIALS AND METHODS 
Animals:  The present study used two strains of mice, the C57/Bl/6J (C57) as the control strain and the low 
density lipoprotein receptor gene deletion (B6.129S7-Ldlrtm1Her/J; LDLr) mice on the C57/Bl/6J 
background.  All mice were purchased from Jackson Laboratories (Bar Harbor, ME) at 8 weeks of age.  
The LDLr gene deletion mouse is a model of human familial hypercholesterolemia, manifesting a 
profound increase in serum LDL levels while ingesting a normal diet (19). 
 Male mice of each strain were fed standard chow and drinking water ad libitum and were housed 
the animal care facility at the West Virginia University Health Sciences Center and all protocols received 
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prior IACUC approval.  At approximately 21 weeks of age, mice were anesthetized with injections of 
sodium pentobarbital (50 mg•kg-1 i.p.), and a carotid artery was cannulated for determination of arterial 
pressure.  Blood aliquots were drawn from the carotid artery cannula for determination lipid profile levels 
(Stanbio), nitrotyrosine (Upstate), TNF-α (Invitrogen), and multiplex cytokine and chemokine levels 
(Millipore).  At this age, the degree of the microvascular dysfunction was not so severe that it would not be 
amenable to amelioration via interventional strategies.  Thus, the use of this age range allows us to examine 
the efficacy of interventional strategies for improving microvascular outcomes. The gastrocnemius 
complex was also removed and snap frozen in liquid N2 immediately after extraction, these were then 
used to run citrate synthase assays, following the manufacturer protocol (Sigma).  
Interventions: At 10 weeks of age, 10 mice from each strain (C57 and LDLr) were placed into one of 
four groups: control, exercise, pharmaceutical treatment, or combined exercise and pharmaceutical 
therapies.  
 Swimming Protocol: The exercise and combination groups participated in swimming twice each 
day separated by a 4-hour rest, 5-days a week for 5-weeks. The mice were acclimated to the swim 
training in 30°C – 34°C water starting with 10-minute sessions increasing daily by 10 minutes until 
reaching the plateau at 90-minutes each session for the remainder of the 5 weeks. This protocol has been 
shown to develop cardiac hypertrophy in normal animals and to minimize and plateau obesity, 
hyperlipidemia, and hypercholesterolemia in db/db mice (9; 27).  
 Pharmaceutical Treatment: The pharmaceutical and combination groups received a combination 
of 1mg/kg/day of ezetimibe (Zetia) and 50 mg/kg/day of simvastatin via chow for 10-weeks, beginning 
at 10 weeks of age. Chow was weighed, recorded, and replaced 2x per week.  
Preparation of Isolated Skeletal Muscle Resistance Arterioles: In anesthetized mice, the intramuscular 
continuation of the right gracilis artery was surgically removed and cannulated, as described previously 
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for rats (14).  These first order arterioles were extended to their approximate in situ length and were 
equilibrated at 80% of the animal's mean arterial pressure in order to approximate the in vivo 
intralumenal pressure experienced by the animal (26).  Following equilibration, arteriolar reactivity was 
evaluated randomly in response to: 1) hypoxia; a reduction in superfusate and perfusate PO2 from ~135 
mmHg (21% O2) to ~40 mmHg (0% O2), 2) acetylcholine (10-10 M – 10-6 M; Sigma), 3) DetaNONOate 
(10-7 M – 10-4 M; Sigma) and 4) thromboxane mimetic U-46619 (10-12 M – 10-8 M; Biomol).  To assess 
the contribution of NO production or the generation of metabolites via cyclooxygenase as mediators of 
arteriolar dilator reactivity, isolated vessels were treated with the NO synthase inhibitor L-NG-
nitroarginine methyl ester (L-NAME; 10-5 M; Sigma) or the cyclooxygenase antagonist indomethacin 
(INDO; 10-6 M; Sigma), respectively. Following assessments of arteriolar reactivity, the perfusate and 
superfusate were replaced with Ca2+-free PSS and vessels were treated with 10-6 M adenosine to 
determine maximum dilation.  
Multiplex Analysis: Whole blood was collected from live animals directly into K2 EDTA containing 
tubes and immediately centrifuged for 10 minutes at 2500 x g. The plasma layer (supernatant) was then 
transferred into 1.5mL microcentrifuge tubes. These tubes were snap frozen in liquid N2 before being 
placed at -80°C for long term storage (< 6 months). Samples were slowly thawed and placed on ice. 
Analysis was performed using multiplex suspension bead array immunoassays on a Luminex 200 
system (Luminex Corporation; Austin, TX). The levels of cytokines were measured using Mouse 
Cytokine, Mouse CVD panels, Mouse CRP Single Plex, and Mouse Soluble Cytokine Receptor panels 
(Millipore; St. Charles, MO) for ICAM, IL-1B, IL-6, IL-10, MCP-1, MMP9, RANTES, sVCAM-1, 
sICAM-1, and e-selectin. Samples were diluted following manufacturer’s recommendations and assayed 
in duplicate in accordance with manufacturer’s instructions. In brief, plates were blocked, after which 
assay buffer, samples and an antibody immobilized bead cocktail were added to each well. The plates 
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were then kept in the dark for all steps subsequent to bead cocktail addition to minimize the effects of 
photobleaching.  Plates were incubated for 18-20 hours at 4°C with agitation, washed, and treated with 
detection antibody. Following 2-hour room temperature incubation with agitation, strepavidin-
phycoerythrin was added to the wells and final 30 minute room temperature incubation with agitation 
performed. Wells were thoroughly washed, beads resuspended in sheath fluid, and the plate was 
analyzed. Concentrations of each cytokine were calculated based on a standard curve generated on the 
same plate and using a 5-parameter logistic fit analysis on Luminex 100 IS software version 2.3.182 
(Luminex Corporation; Austin, TX).  
Western Blot Analysis: Pooled isolated non-aortic conduit vessels were snap frozen in liquid N2 
immediately after extraction. Protein was harvested from by repeated vortexing and boiling in a sample 
buffer containing 0.045M Tris-Cl pH 6.8, 10% by volume glycerol, 1% by volume SDS, 0.05M 
dithiothreotol, and 1% by volume 2-Mercaptoethanol, however to detect phosphorylation eNOS species, 
eNOS affinity purified from cell lysates using 2’,5’- ADP-Sepharose (Pharmacia). Protein for eNOS 
phosphorylation will be size fractionated by SDS-PAGE. The total protein concentration of each sample 
was determined using a Nano-Orange assay (Invitrogen, California) according to the manufacturer’s 
protocol. For each gel, protein samples were diluted in sample buffer to an equal concentration, boiled 
for 10 min and spun for 10 min at 9300 x g prior to loading onto precast 10% Bis-Tris polyacrylamide 
gels (Invitrogen, California). Gels were loaded with 50ug of total protein per well. Electrophoresis was 
be carried out at 150V for 1.5 h and resolved proteins were transferred to an Immobilon PVDF 
membrane (Millipore, Massachusetts) at 30V for 1.25 hours using Invitrogen’s Sure Lock Mini-Cell 
electrophoresis system and associated X-Cell II Blot Module. Membranes were blocked overnight at 
4°C in Superblock T-20 (Pierce Biotechnology, Illinois) and then incubated with associated antibodies 
eNOS (B&D) or ph-eNOS (Zymed) for an additional 1.5 hours. Membranes were then washed and 
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incubated with appropriate horseradish peroxidase conjugated secondary antibody. Amersham ECL 
western blotting kits were used to visualize proteins. Membranes were subsequently washed and 
incubated with GAPDH-HRP antibody for 1 hour, washed, visualized using an Amersham ECL western 
blotting kit, and measured using densitometry (11). 
Data and Statistical Analyses:  Active tone of individual arterioles at the equilibration pressure was 
calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from rest in response to Ca2+-free PSS, 
and Dmax is the maximum diameter measured at the equilibration pressure in Ca2+-free PSS.   
 Dilator responses of isolated arterioles following challenge with dilator agonists were fit with the 
four-parameter logistic equation: 
⎥⎦
⎤⎢⎣
⎡
+
−+= −xEDy 50log101
minmaxmin  
where y  represents the change in arteriolar diameter, “min” and “max” represent the lower and upper 
bounds, respectively, of the change in arteriolar diameter with increasing agonist concentration, x  is the 
logarithm of the agonist concentration and 50log ED  represents the logarithm of the agonist concentration (
x ) at which the response ( y ) is halfway between the lower and upper bounds.     
 Data are presented as mean±SEM.  Statistically significant differences in measured and calculated 
parameters in the present study were determined using analysis of variance (ANOVA).  In all cases, Holm-
Sidak test was used when appropriate and p<0.05 was taken to reflect statistical significance.   
RESULTS 
 Table 1 presents baseline characteristics of the eight mouse groups used in the present study.  While 
all mice were of comparable MAP at 20 weeks of age, the mice in each of the three treatment groups show 
a significant lower mass than the control groups with the exception of the C57 combination group. The 
LDLr animals also show a profound hypercholesterolemia, significantly aided by the interventions, but not 
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bringing the levels back to a control state. The control animals also show significant cholesterol reductions 
within the treatment groups.  Interestingly, the LDLr animals had a significantly larger outer diameter at the 
start of the experiments; however the active tone was significantly lower in all of the treatments groups of 
the control mice with no change in the LDLr group.  
 Figure 1 presents dilator reactivity for isolated arterioles from C57 and LDLr control mice in 
response to hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B), detaNONOate 
(Panel C), U-46619, a thromboxane mimetic (Panel D).  In response to the endothelium-dependent dilation 
challenges of hypoxia and acetylcholine, responses in vessels from LDLr mice were attenuated compared to 
the C57 control responses. When L-NAME is added, inhibiting NOS activity, the LDLr animals show a 
mild attenuation of the dilator reactivity, while the control animals show a blunted response. In response to 
indomethacin, a   cyclooxygenase inhibitor, there is a mild reduction in control activity, while the LDLr 
group shows a greater loss of reactivity. In combination, these two inhibitors lead to an abolishment of 
control activity, however, there is a significant endothelium-dependent arteriolar dilation remaining in the 
LDLr animals. In Panel C (detaNONOate), where dilator responses are endothelium-independent, or in 
Panel D (U-46619), there were no significant differences at control or with the inclusion of either of the 
inhibitors, singly or in combination.  
 Figure 2 presents vascular reactivity of isolated skeletal muscle resistance arterioles in control and 
after cholesterol lowering treatment at control and following pharmaceutical inhibition of eNOS (L-NAME) 
and cyclooxygenase (INDO), and the combination of both pathways in response to hypoxia (Panel A) and 
to increasing concentrations of acetylcholine (Panel B), DetaNONOate (Panel C), and U-46619 (Panel D), 
of C57 mice, while Figure 3 presents these outcomes in LDLr mice. In response to the endothelium-
dependent dilation challenges of hypoxia and acetylcholine C57 mice demonstrated a decreased arteriolar 
reactivity after pharmaceutical therapy; however these changes are not mimicked within the LDLr mice. 
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When challenged with L-NAME (Panel B) this significant difference between the control and 
pharmaceutically treated control is evident, as there is a residual dilation associated with the cholesterol 
lowering treatment. There are no significant differences between the groups with the COX inhibitor 
indomethacin (Panel B) or in combination with NOS inhibition (Panel B). There were no significant 
differences using detaNONOate (Panel C) or U-46619 (Panel D), with respect to the pharmaceutical 
treatment in either the control or hypercholesterolemic group.  
 Figure 4 presents control vascular reactivity and following pharmaceutical inhibition of eNOS (L-
NAME) and cyclooxygenase (INDO), and the combination of both pathways in response to hypoxia (Panel 
A) and to increasing concentrations of acetylcholine (Panel B), DetaNONOate (Panel C), and U-46619 
(Panel D) of isolated arterioles of C57 and LDLr mice (Figure 5) under control conditions and after exercise 
treatment. Hypoxia-induced dilation was pronounced in vessels that were within the exercise treatment 
from C57 and demonstrated a progressive attenuation as L-NAME and Indo were added to the bath, 
individually and in combination. Additionally, these significant differences were mirrored within the 
acetylcholine treatment. There were no significant differences within the control group with respect to the 
increasing concentrations of DetaNONOate (Panel C) or U-46619 (Panel D). There were no significant 
differences within the LDLr groups. 
 Figure 6 presents vascular reactivity of control and cholesterol lowering therapies combined with 
exercise in response to hypoxia (Panel A) and to increasing concentrations of acetylcholine (Panel B), 
DetaNONOate (Panel C), and U-46619 (Panel D) in isolated arterioles of C57 and LDLr (Figure 7) mice 
under control conditions and following pharmaceutical inhibition of eNOS (L-NAME) and cyclooxygenase 
(INDO), and the combination of both pathways. At control, both the C57 and LDLr animals show an 
attenuation of activity with respect to the combination treated counterparts after hypoxia and increasing 
concentrations of acetylcholine at baseline. With respect to the inhibitors, the C57 group shows differences 
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with the combination L-NAME/Indo inhibition; whereas LDLr animals show significance between with all 
inhibitors, L-NAME, Indo, and the combination of the two. There were no significant differences when 
challenged to DetaNONOate (Panel C) or U-46619 (Panel D).     
 Figure 8 presents the representative western blot and densitometry analysis of eNOS. These figures 
indicate that there are no significant differences between the groups.   
 Lastly, Table 2 presents the cytokine and chemokine analysis. This figure shows significantly higher 
values of citrate synthase within the exercise and combination treatments compared to the control and 
pharmaceutical treatment groups; however the combination group was also significantly lower when 
compared to the exercise group alone. The LDLr exercise group, with respect to nitrotyrosine is 
significantly lower than all other groups, including the control and the paired C57 group. With respect to 
CRP, the exercise groups are significantly lower than any of the treatment or control groups; additionally, 
the combination treatment groups are significantly lower than the control and pharmaceutical treatment 
groups, but not as effective as exercise alone. With respect to e-selectin, the control groups are significantly 
higher than all of the treatment groups. The MMP-9 results show that the combination treatment groups are 
significantly higher than the other groups. In regard to icam, the control exercise group is significantly 
higher than the other groups, while in the LDLr groups, the treatment groups are significantly different than 
the control; however the direction is inconsistent. However, with respect to vcam, the control and 
pharmaceutical groups are significantly higher than the exercise and combination treatments. When 
evaluating IL-6 and IL-10 levels, the LDLr control group is significantly higher than any of the treatment 
groups, while no significant differences are seen within the C57 groups.  
DISCUSSION 
 While the evolution of hypercholesterolemia has been shown to be a key risk factor leading to 
the development of cardiovascular disease, due to modifications to vascular structure and endothelial 
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function, alterations within the microcirculation is directly coupled to endothelial cell dysfunction (3; 8; 
15; 18; 39; 49). Previous studies have shown this dysfunction to be directly related to decreases in 
vascular nitric oxide (NO) bioavailability, elevated oxidant stress, and a strongly pro-inflammatory state; 
however these prior studies have not investigated interventions which may improve these consequences 
and, in turn, decrease cardiovascular disease risk (3; 4; 12; 19; 31; 39; 41; 42; 46; 48).  
 The primary observation of this study is that the traditional interventional strategies of 
pharmaceutical therapy and exercise treatment associated with hypercholesterolemia are not effective 
strategies to improve vascular reactivity (Figure 2-4) or increase eNOS expression (Figure 8); however, 
exercise alone was shown to be effective to improve oxidative stress and inflammation (Table 2). 
Unexpectedly, the pharmaceutical and combination therapies were shown to be detrimental to the 
control group (Figure 2 and 4). However, the mechanism of the decrease is not directly related to 
changes associated with oxidative stress or inflammation (Table 2). This decrease may be due to 
asymmetric dimethylarginine (ADMA) an endogenous inhibitor of eNOS activity due to competition 
with L-arginine leading to a reduction of nitric oxide bioavailability (22). ADMA has been shown to be 
elevated in hypercholesterolemic mice and show strong correlations to a decrease in low-mediated 
dilation in human hypercholesterolemic populations (2; 46; 47). 
 Previous studies have suggested that the condition of hypercholesterolemia leads to a decrease in 
NO bioavailability and therefore compensatory mechanisms of arachidonic acid metabolism act to 
maintain endothelium-dependent dilation (12; 39). Additional studies have shown that this decrease in 
NO bioavailability may be due to a pro-inflammatory state coupled with high oxidative stress, leading to 
oxidative scavenge of available NO compounded with eNOS uncoupling, creating the perfect storm to 
decrease NO (42; 43).  
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The rescue of NO has been shown to be linked to a number of pleiotropic effects of 
pharmaceutical treatments currently available on the market. These drugs have been shown to reduce 
inflammation and oxidative stress, despite elevated cholesterol levels. Some studies have shown positive 
results with respect to lipid peroxidation, including the increase of an antioxidant effect leading to a 
decrease in ox-LDL with combination ezetimibe/statin treatment (17). A number of studies are currently 
ongoing to determine if the anti-inflammatory and anti-oxidative pleiotropic effects would be beneficial 
to normocholesterolemic patients, specifically to managing inflammation and preventing atherosclerotic 
lesions (44; 51). These studies have been met with mixed reviews and results. Many of these results 
have been difficult to discern in traditional studies, as discrete results in the hypercholesterolemic 
populations are very similar to results directly attributed to the cholesterol lowering benefit. Our results 
suggest that these pharmaceutical agents may in fact be detrimental to patients who are not 
hypercholesterolemic.      
 It has previously been demonstrated that a moderate intensity exercise program can also lead to 
an increase in NO bioavailability, through acute shear stresses, improvements in mitochondrial anti-
oxidative mechanisms, and through a decrease in the low-grade pro-inflammatory phenotype due to 
myokine activation (7; 26; 29; 49). CRP has been shown to reduce eNOS activity, promote eNOS 
uncoupling, and alter eNOS phosphorylation, overall limiting NO bioavailability (33; 35; 45). In this 
study, while exercise did not lead to a significant improvement in vascular reactivity, improvements to 
overall oxidative stress and inflammatory marker profile were evident with respect to CRP, MCP-1, 
RANTES, and nitrotyrosine. This suggests that overall improvements are being made to the mechanisms 
affecting NO bioavailability, and perhaps improvements to reactivity may be evident over a longer 
training period. 
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 Combining the two therapies used in this study lead to a combination of the results seen 
independently. Interestingly, the combination treatment leads to a detriment to the vascular reactivity, in 
both the control and hypercholesterolemic groups. While only a moderate improvement was made with 
respect to CRP and RANTES levels, unlike the drastic improvements seen with exercise alone. In icam 
and vcam measurements, significant reductions were also evident when comparing the combination 
groups to the control and single interventions. However, this improvement was not evident when 
examining nitrotyrosine levels. Interestingly, the combination treatment seems to impact to amount of or 
efficiency of the exercise that is performed, as citrate synthase levels are significantly lower than that of 
the exercise groups independently. However, at present, the side effects of the combined therapy are not 
well described, and it is unclear how effective these are for impacting the inflammatory and oxidative 
profiles (21; 23; 36). 
 Taken together, the results of the present study suggest that exercise alone may be the most 
beneficial intervention for hypercholesterolemic condition. However, as our model only evaluated the 
pleiotropic effects of the ameliorative therapies, with respect to human patient, the exercise treatment in 
combination with the direct cholesterol lowering effects of pharmaceutical treatment, may lead to the 
greatest benefit. However, this treatment is not suggested to a population who are considered 
normocholesterolemic, as the mechanisms leading to the detriment to the vascular reactivity within this 
group need further exploration. Additionally, the anti-oxidative and anti-inflammatory benefits 
pertaining to the exercise only group are much greater than the pleiotropic effects within the 
pharmaceutical or combination groups. In conclusion, the mechanisms specific to improvements within 
the microcirculation of hypercholesterolemic patients warrants further review. The interventional 
strategies need to be evaluated with respect to their direct cholesterol lowering benefits and pleiotropic 
effects within a normocholesterolemic and hypercholesterolemic populations.  
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FIGURE AND TABLE LEGENDS 
Table 1. Baseline and treatment characteristics of mice and individual arterioles used in the present study. 
*p<0.05 vs. C57. 
 
 
 
    Control 
C57 
Control  
LDLr 
Statin  
C57 
Statin  
LDLr 
Exercise 
C57 
Exercise  
LDLr 
Combo  
C57 
Combo 
 LDLr 
Age (weeks)   21.78  ± 0.18 
21.00† 
± 0.15 
21.33 
± 0.31 
22.14* 
± 0.33 
22.29 
± 0.07 
22.17* 
± 0.13 
24.50 
± 0.14 
24.67* 
± 0.09 
Weight   32.14 ± 0.28 
31.77† 
± 0.37 
27.47 
± 0.26 
28.19* 
± 0.29 
26.43 
± 0.20 
26.43* 
± 0.58 
26.73 
± 0.15 
24.30* 
± 0.08 
MAP   87.00 ± 1.27 
87.20† 
± 1.18 
78.00* 
± 1.17 
77.57*† 
± 1.12 
80.29* 
± 1.38 
71.33*† 
± 1.55 
87.00 
± 2.54 
77.60*† 
± 1.79 
Weeks 
Pharmaceuticals 
 /Exercise  
‐  ‐    9.35 ± 0.31 
9.98 
± 0.35 
4.71 
± 0.07 
4.76 
± 0.08 
13.79  
± 0.11 
13.67  
± 0.08 
5.00  
± 0.10 
4.90  
± 0.07 
Passive Diameter                 
Inner Pre   44.67  ± 1.23 
46.50   
± 1.30 
50.33
± 2.34 
44.86
± 0.89 
51.43
± 1.41 
55.50
± 2.62 
50.83  
± 1.63 
46.17
± 1.61 
Outer Pre   69.22 ± 1.25 
73.33† 
± 1.74 
69.50 
± 2.83 
66.00† 
± 0.93 
68.14 
± 1.50 
70.83† 
± 2.61 
69.33* 
± 1.51 
65.33† 
± 2.30 
Inner Post   70.89 ± 1.05 
68.83† 
± 1.60 
71.50 
± 2.23 
67.14*† 
± 1.27 
77.71 
± 1.35 
85.67 
± 2.32 
76.17 
± 1.70 
71.17* 
± 1.45 
Outer Post   90.89 ± 1.03 
85.17 
± 2.64 
88.83
± 2.77 
83.14
± 1.05 
88.14
± 1.52 
96.50
± 2.06 
89.67* 
± 2.00 
84.67
± 1.78 
       
Active Tone (%)   37.89 ± 1.17 
33.53†  
± 0.83 
31.26* 
± 1.29 
32.99 
± 0.81 
34.07* 
± 1.19 
36.10 
± 1.82 
33.98* 
± 1.11 
35.66 
± 1.64 
Total 
Cholesterol 
103.30 
± 2.48 
(n=8) 
236.84† 
± 2.92 
(n=10) 
79.16* 
± 1.26 
(n=9) 
199.05*† 
± 5.10 
(n=9) 
67.74* 
± 0.99 
(n=10)  
213.03*† 
± 3.18 
(n=10) 
83.89* 
± 4.21 
(n=10) 
184.92*
† 
± 3.29 
(n=10) 
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 Table 2. Baseline and treatment plasma profile characteristics of mice used in the present study. * p<0.05 
vs. C57. 
 
 
 
 
 
 
 
 
    Control 
C57 
Control 
LDLr 
Statin  
C57 
Statin  
LDLr 
Exercise  
C57 
Exercise  
LDLr 
Combo 
C57 
Combo 
LDLr 
CRP (ng/mL)  82.93 ± 3.46  81.12 ± 2.58  78.66 ± 1.47 79.73 ± 1.05 33.52 * ± 0.61 
35.52 * 
 ± 0.30 
50.55 *
± 0.85 
52.79 *
± 1.05 
           
IL­1B (pg/mL)  46.69 ± 7.09  27.12 ± 1.01  22.40 ± 2.04 31.25 ±4.59  3.22 ± 0.00  174.03 *† 
± 94.97 
35.86 ± 4.46 21.57 ± 0.69
IL­6 (pg/mL)  54.61 ± 6.80  70.44 ± 16.09  27.81 ± 4.57 11.99 ± 0.60 n/a  5.82 ± 1.95 
44.86 ± 
12.23 
14.51 ± 0.63
IL­10 (pg/mL)  50.02 ± 4.72  142.20 †  
± 33.70 
36.94 ± 2.56 23.65 * ± 1.57     n/a  64.35 ±0.00  23.15 ± 3.85
14.48 † ± 
0.73 
                     
e­selectin  132.23 ± 12.04 
88.99 † 
 ± 5.49 
78.43 *
± 9.03 
51.95 *† 
± 1.60 
41.08 *  
±  0.56 
53.84 * 
±1.21 
46.09 * 
± 1.17 
45.58 * 
± 1.76 
mmp­9   2.27 ± 0.21  2.98 ± 0.24  1.73 ± 0.11  1.35 ±0.12 
3.09 * 
± 0.38 
2.11 *†  
± 0.13 
6.00 * 
± 0.23 
4.39 *†  
±0.17 
icam   1098.34  ± 14.04 
984.80 † 
± 23.26 
1169.47 ± 
24.05 
1067.76 * 
± 18.35 
1226.20 * 
± 27.39  
1090.05 *†  
± 29.03 
956.57 * 
± 31.54 
872.91 *† 
± 38.03 
Vcam  20.77 ± 0.49  18.30 *± 0.35 18.34 *± 0.51 17.45 ± 0.32 14.87 *± 0.46 
15.20 * 
± 0.41 
14.48 *
± 0.27 
13.91 *
± 0.36 
 
           
       
Nitrotyrosine   3.03 ± 0.10  3.59 ± 0.19  2.14 ± 0.08  3.16 ± 0.63 
2.83 ± 
0.24  1.91 *†± 0.25 3.05 ± 0.18  3.22 ± 0.20 
TNFα   4.34 ± 0.28  2.90 ± 0.30  4.08 ± 0.45 2.23 ± 0.00 3.09 * ± 0.23 5.23 *± 0.12  2.61 *± 0.17 4.44 * ± 0.24
Citrate 
Synthase   51.06 ± 4.82   53.47 ± 4.17  59.32 ± 2.39  63.17 ± 2.96 
155.12 *
± 13.35  
173.99 * 
± 19.65  
104.16 *
± 6.62  
90.62 *
± 6.57  
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Figure 1.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles under 
control conditions of C57 and LDLr mice and following pharmacological inhibition of nitric oxide synthase 
with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition of both enzymatic 
pathways in response to hypoxia (Panel A), and increasing concentrations of acetylcholine (Panel B), 
detaNONate (Panel C) and describing the constrictor reactivity in response to increasing concentrations of 
U-46619 (Panel D). Data, presented as mean±SEM, are shown for arterioles under control conditions and 
associated stimuli.  n=4-14 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs. control within that strain. 
 
Figure 2.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57 mice 
at control and pharmaceutically treated conditions at control and following pharmacological inhibition of 
nitric oxide synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition 
of both enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of 
acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of 
U-46619 (Panel D). n=4-14 animals for each strain; * p<0.05 vs. C57; † p<0.05 vs. control within that 
strain. 
 
Figure 3.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of LDLr 
mice at control and pharmaceutically treated conditions at control and following pharmacological inhibition 
of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined 
inhibition of both enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of 
acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of 
U-46619 (Panel D). n=4-11 animals for each treatment; * p<0.05 vs. C57; † p<0.05 vs. control within that 
strain. 
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Figure 4.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57 mice 
at control and exercised animals at control and following pharmacological inhibition of nitric oxide 
synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition of both 
enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of acetylcholine 
(Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of U-46619 (Panel 
D). n=4-14 animals for each treatment; * p<0.05 vs. C57; † p<0.05 vs. control within that strain. 
 
Figure 5.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of LDLr 
mice at control and exercised animals at control and following pharmacological inhibition of nitric oxide 
synthase with L-NAME, cyclooxygenase with indothemation (INDO) or combined inhibition of both 
enzymatic pathways in response to hypoxia (Panel A) and increasing concentrations of acetylcholine 
(Panels B), detaNONate (Panel C) and constrictor reactivity to increasing concentrations of U-46619 (Panel 
D). n=4-11 animals for each treatment; * p<0.05 vs. C57; † p<0.05 vs. control within that strain. 
 
Figure 6.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of C57 mice 
at control and combination pharmaceutically treated and exercised animals at control and following 
pharmacological inhibition of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation 
(INDO) or combined inhibition of both enzymatic pathways in response to hypoxia (Panel A) and 
increasing concentrations of acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to 
increasing concentrations of U-46619 (Panel D). n=4-14 animals for each treatment; * p<0.05 vs. C57; † 
p<0.05 vs. control within that strain. 
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Figure 7.  Data describing the dilator reactivity of isolated skeletal muscle resistance arterioles of LDLr 
mice at control and combination pharmaceutically treated and exercised animals at control and following 
pharmacological inhibition of nitric oxide synthase with L-NAME, cyclooxygenase with indothemation 
(INDO) or combined inhibition of both enzymatic pathways in response to hypoxia (Panel A) and 
increasing concentrations of acetylcholine (Panels B), detaNONate (Panel C) and constrictor reactivity to 
increasing concentrations of U-46619 (Panel D). n=4-11 animals for each treatment; * p<0.05 vs. C57; † 
p<0.05 vs. control within that strain. 
 
Figure 8.  Representative western blot and densitometry data describing eNOS (Panel A) responses of 
pooled isolated skeletal muscle resistance arterioles of control C57 and LDLr mice in addition to 
pharmaceutically treated, exercised, and combination therapies mice. Data, presented as mean±SEM.  n=3 
animals for each group; * p<0.05 vs. control conditions in that strain. 
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DISCUSSION 
 The purpose of this study was to investigate the condition of hypercholesterolemia and 
how it relates to adaptations to vascular reactivity and the mechanisms behind endothelium 
dependent dilation. Hypercholesterolemia has been associated with endothelial cell dysfunction 
at all levels of vasculature, including the microcirculation (1; 3; 6; 14; 16; 36; 43). These reports 
have also described impairments to vascular reactivity compared to normocholesterolemic 
patients (2; 5; 8; 15; 24; 34).These alterations and attenuated responses have been implicated in 
stemming from elevations in pro-inflammatory and oxidant stress markers, while NO 
bioavailability is severely blunted due to reductions in production or oxidative scavenge (3-5; 8; 
10; 17-20; 24; 30; 36; 38-42). The investigation into these hypercholesterolemic consequences as 
they relate to vascular reactivity and the mechanisms by which they occur are currently under 
evaluation.  
The first study, Differential Impact of Familial Hypercholesterolemia and Combined 
Hyperlipidemia on Vascular Wall and Network Remodeling in Mice, examined the differences 
and temporal progression of microvascular remodeling within conditions of 
hypercholesterolemia and hyperlipidemia. Additionally, this study compared and evaluated the 
mechanical alterations with plasma inflammatory biomarkers to observe the global or systemic 
outcomes within the three models control, familial hypercholesterolemia (FH), and familial 
combined hyperlipidemia (FCH). While a number of groups have evaluated the mechanistic 
alterations associated with dyslipidemia, these data indicate that the net modifications within 
dyslipidemia is not due solely to mechanistic variations, but to complicated mechanical 
alterations as well (28; 31; 36; 43). Our results indicate that while there is an extensive 
remodeling associated within the condition dyslipidemia, the specifics of the remodeling 
172
between the two strains differs. Within the FH condition, the remodeling was within the 
resistance arterial wall, thereby increasing wall stiffness; additionally, cholesterol severity and 
inflammatory markers of cell attraction and adhesion (MCP-1) can be implicated in the early 
onset increase in wall thickness and stiffness. However, within the FCH condition, the 
remodeling was specific to the microvascular networks through an increase of rarefaction with a 
reflective increase in pro-inflammatory markers (TNF-α) of inflammation leading to significance 
at a later age. This increase in rarefaction or reduction in vascular density has been proposed to 
contribute to an increase in peripheral resistance and cause variations in oxygen delivery within 
the vascular network (12). While vascular nitric oxide bioavailability and PGI2 prove to be poor 
discriminators of vascular remodeling within conditions of dyslipidemia, TxA2 production is more 
significant and maintained at an earlier age within the FCH animals. Taken together, this study 
indicates that while there is significant remodeling leading to poor vascular outcomes within the 
condition of dyslipidemia; the mechanical remodeling differs with respect to the resulting 
dysfunction and temporal progression specific to the conditions of hypercholesterolemia and 
hyperlipidemia.  
 The second study, Altered Mechanisms of Endothelium-Dependent Dilation in Skeletal 
Muscle Arterioles with Genetic Hypercholesterolemia, examined the effects of 
hypercholesterolemia on the mechanisms of endothelium-dependent dilator responses of skeletal 
muscle resistance arterioles. While the progression and outcomes of the mechanical alterations 
differ, past research has shown that the dilator responses to shear and metabolic stimuli are 
overwhelmingly intact, despite diminished activity or bioavailability of endogenous NO (7; 29). 
While other groups have suggested that hypercholesterolemic animals show alterations in the 
endothelium-dependent dilator responses to acetylcholine and the metabolites of arachidonic acid 
173
(32; 44). This study focuses on the maintenance of dilator reactivity despite use of alternative 
endothelium dependent pathways. Our results show that the endothelium dependent dilator 
reactivity is maintained, although the signaling mechanism to attain this dilation is altered. The 
signaling mechanism related to prostacyclin metabolism and activity is preserved, while NO 
bioavailability is diminished. With this reduction in NO bioavailability, 12- and 15-lipoxygenase 
emerge as a compensatory mechanism to sustain appropriate endothelium dependent dilation. 
This alteration suggests variations to the arachidonic acid metabolism in hypercholesterolemic 
animals.         
 The third study, Increased Arachidonic Acid-Induced Thromobxane Generation Impairs 
Skeletal Muscle Arteriolar Dilation with Genetic Dyslipidemia, examined the dilator reactivity to 
direct challenges of increased concentrations of arachidonic acid to explore the 
hypercholesterolemic alterations to the metabolism of arachidonic acid in production and 
vascular responses to the metabolites.  Past research has strongly indicated a change to 
arachidonic acid metabolism, specifically, showing improvements to reactivity using 
cyclooxygenase inhibitors and animals lacking functional thromboxane receptors (27; 35).  This 
study evaluated the production and vascular reactivity to arachidonic acid metabolism through 
the cyclooxygenase pathway specific to the condition of hypercholesterolemia. Our results 
indicate that there is a dilator impairment of hypercholesterolemic arterioles to increasing 
concentrations of arachidonic acid. These impairments do not stem from an alteration of 
prostacyclin production or activity; increases in thromboxane generation and activity, however 
can account for these decreases in dilator reactivity. Therefore, within the condition of 
hypercholesterolemia, altered mechanisms of arachidonic acid metabolism lead to a greater 
thromboxane generation. The amount of thromboxane then competes with the amount of 
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prostacyclin and lipoxygenase produced leading to decreased overall dilator reactivity in 
response to arachidonic acid metabolism. This shift in metabolism may be due to an increase in 
vascular oxidant stress.            
 The fourth study, Impaired Skeletal Muscle Arterial Endotheluim-Dependent Dilation in 
Familial Hypercholesterolemia: Impact of Chronic Exercise and Anti-Cholesterol Therapies, 
evaluated dilator reactivity and NO bioavailability after chronic ameliorative therapies. 
Hypercholesterolemia has emerged as a consistently manageable risk factor for CVD and past 
research has shown a number of vascular protective effects directly associated with a decrease in 
cholesterol levels, these effects are evident with natural cholesterol lowering treatments such as 
diet and exercise, along with pharmaceutical treatments. Additionally, many cholesterol lowering 
drugs have been linked to a number of anti-inflammatory and anti-oxidative pleiotropic effects 
that may lead to improvements in vascular reactivity (9; 11; 13; 21-23; 25; 26; 33; 37). This 
study focused on interventional strategies improving the vascular reactivity and NO 
bioavailability of the hypercholesterolemic animals. We found that the cholesterol lowering 
therapy did not improve the vascular reactivity of the hypercholesterolemic animals; in contrast, 
the treatment was damaging to the control animals. Overall, the effects of the cholesterol 
lowering treatments are beneficial with respect to the control group was detrimental and made no 
significant difference within the hypercholesterolemic animals. The exercise treatments alone 
were most beneficial to both groups. This treatment leads to an overall decrease in CRP, 
indicating a decrease in the overall inflammatory profile, much greater than the effects found in 
either of the other treatment groups.        
 In future studies of the endothelium dependent dilator vascular reactivity of 
hypercholesterolemia, there are a number of areas which warrant further investigation. Initially, 
175
many groups have identified a decrease in the bioavailability of NO; the signaling mechanism 
behind this reduction may open a number of therapeutic avenues for hypercholesterolemic 
patients. Additionally, to determine the alterations leading to the increase in thromboxane 
generation and the shift leading to an increase in vascular oxidants. With respect to the 
interventional strategies, there are a number of conflicting reports regarding the existence of and 
mechanisms behind the pleiotropic effects associated with the cholesterol lowering 
pharmaceuticals. Furthermore, the mechanisms leading to the detrimental effect to the vascular 
reactivity evident in the control group also warrants further exploration.  
 In conclusion, hypercholesterolemia is a modifiable risk factor associated with 
cardiovascular diseases, including peripheral vascular and coronary heart disease. There have 
been numerous studies evaluating mechanical alterations and endothelial cell dysfunction leading 
to the impairments associated with dyslipidemic vascular reactivity. These impairments have 
been correlated with decreases in NO bioavailability, alterations in arachidonic acid metabolism, 
increases in vascular oxidants, and a pro-inflammatory condition. These studies assessed the 
mechanical alterations leading to poor vascular outcomes, compensatory mechanisms to 
maintain endothelium dependent dilator reactivity within the hypercholesterolemic condition, 
alterations to arachidonic acid metabolism, and evaluated the pleiotropic effects of a number of 
ameliorative cholesterol-lowering therapies. These results suggest that the while extensive 
remodeling is evident within the progression of dyslipidemia, there are significant differences 
between temporal development and overall outcome of FH and FCH leading to an earlier 
development of wall stiffness and thickness produced in part by increases in MCP-1  within FH, 
while the condition of FCH leads to a later progression of microvascular rarefaction, due to an 
increase of apoptotic markers including TNF-α; vascular function within the 
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hypercholesterolemic condition is maintained via the 12- and 15-lipoxygenase pathways of 
arachidonic acid metabolism, despite decreased NO bioavailability; arachidonic acid metabolism 
via the cyclooxygenase pathway is altered, leading to a greater production of thromboxane A2 
competing with prostacyclin availability thereby reducing net dilation; and clinically relevant 
pharmaceutical ameliorative therapies detrimentally impact normocholesterolemic endothelium 
dependent dilation, while making no impact on hypercholesterolemic microvessels independent 
of the cholesterol lowering effects of these drugs, however, exercise or combination therapies 
may yield the greatest benefit in both groups, as the anti-inflammatory and anti-oxidative effects 
hold the greatest promise in producing beneficial outcomes for both normo- and 
hypercholesterolemic conditions. The mechanistic and mechanical outcomes of these 
interventions are not well understood and require further evaluation within the realms of 
inflammation, oxidative stress, and vascular reactivity within the normo- and 
hypercholesterolemic conditions to provide the most beneficial effects.  
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